


Cell Reports

Single-Cell and Population Transcriptomics Reveal Pan-epithelial Remodeling in Type 2-High Asthma

Graphical Abstract



Authors

Nathan D. Jackson, Jamie L. Everman, Maurizio Chioccioli, ..., Nichole Reisdorph, Esteban G. Burchard, Max A. Seibold

Correspondence

seiboldm@njhealth.org

In Brief

Using airway epithelial cell cultures, Jackson et al. show that IL-13, a driver of type 2-high asthma, induces emergent mucin secretory expression states for each cell type. This program universally diminishes innate airway defense, produces a pathologic mucus secretome that arrests mucociliary movement, and is recapitulated in type 2 inflamed children.

Highlights

- IL-13 alters secretory expression states in all airway epithelial cell types
- Chronic IL-13 weakens innate defense but spurs interferon signaling in ciliated cells
- IL-13 reprogramming leads to pathologic mucus that slows ciliary beat frequency
- IL-13-induced metaplasia recapitulates reprogramming in type 2 inflamed children



Resource

Single-Cell and Population Transcriptomics Reveal Pan-epithelial Remodeling in Type 2-High Asthma

Nathan D. Jackson,¹ Jamie L. Everman,¹ Maurizio Chioccioli,^{2,9} Luigi Feriani,² Katherine C. Goldfarbmuren,¹ Satria P. Sajuthi,¹ Cydney L. Rios,¹ Roger Powell,³ Michael Armstrong,³ Joe Gomez,³ Cole Michel,³ Celeste Eng,⁴ Sam S. Oh,⁴ Jose Rodriguez-Santana,⁵ Pietro Cicuta,² Nichole Reisdorph,³ Esteban G. Burchard,^{4,6} and Max A. Seibold^{1,7,8,10,*}

¹Center for Genes, Environment, and Health, National Jewish Health, Denver, CO 80206, USA

²Department of Physics, University of Cambridge, Cambridge, CB2 3AX, UK

³Department of Pharmaceutical Sciences, University of Colorado-AMC, Aurora, CO 80045, USA

⁴Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA

⁵Centro de Neumología Pediátrica, San Juan, PR 00917, USA

⁶Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94158, USA

⁷Department of Pediatrics, National Jewish Health, Denver, CO 80206, USA

⁸Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado-AMC, Aurora, CO 80045, USA

⁹Present address: Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA

¹⁰Lead Contact

*Correspondence: seiboldm@njhealth.org

<https://doi.org/10.1016/j.celrep.2020.107872>

SUMMARY

The type 2 cytokine-high asthma endotype (T2H) is characterized by IL-13-driven mucus obstruction of the airways. To further investigate this incompletely understood pathobiology, we characterize IL-13 effects on human airway epithelial cell cultures using single-cell RNA sequencing, finding that IL-13 generates a distinctive transcriptional state for each cell type. Specifically, we discover a mucus secretory program induced by IL-13 in all cell types which converts both mucus and defense secretory cells into a metaplastic state with emergent mucin production and secretion, while leading to ER stress and cell death in ciliated cells. The IL-13-remodeled epithelium secretes a pathologic, mucin-imbalanced, and innate immunity-depleted proteome that arrests mucociliary motion. Signatures of IL-13-induced cellular remodeling are mirrored by transcriptional signatures characteristic of the nasal airway epithelium within T2H versus T2-low asthmatic children. Our results reveal the epithelium-wide scope of T2H asthma and present candidate therapeutic targets for restoring normal epithelial function.

INTRODUCTION

Asthma is a chronic disease of the airways marked by clinical features that include airway hyperresponsiveness and reversible airway obstruction. Although united by these clinical features, asthmatics exhibit heterogeneous pathobiology, with distinct endotypes driving development and persistence of disease (Fahy, 2015). The most common asthma endotype is characterized by airway inflammation triggered by type 2 (T2) cytokines (IL-4, IL-5, and IL-13). Referred to as T2-high (T2H), this endotype affects not only 50% of asthmatics but also a subgroup of chronic obstructive pulmonary disease (COPD) patients (Barceló et al., 2006; Christenson et al., 2015; George and Brightling, 2016). Thus, the particular features of T2H disease, including severe hyperresponsiveness, eosinophilia, and mucus overproduction, may underlie a more general form of airway pathobiology relevant to many airway and lung diseases (Poole et al., 2014; Woodruff et al., 2009).

Although T2H asthma involves multiple tissue types, dysfunction of the airway epithelium is central to development, pathology, and persistence of this disease endotype (Kuperman et al., 2002). Positioned at the interface between the inhaled environment and the lung, the airway epithelium forms a physical barrier and generates the mucociliary escalator that clears inhaled particulates and microorganisms. Moreover, the airway epithelium generates defensive secretions critical to innate immunity that contain growth factors, cytokines, and chemokines that stimulate and direct the activity of airway immune cells. These higher order epithelial functions are the cumulative products of a functionally diverse set of cell types and intermediate states that populate the healthy airway in particular proportions (Montoro et al., 2018; Plasschaert et al., 2018). Studies using bulk transcriptomics and histology make clear that both the function and relative frequency of epithelial cell types are altered in T2H asthma and chronic airway diseases (Bergeron et al., 2009; Fahy, 2015; Poole et al., 2014), yet the imprecision (bulk






Figure 1. Outline of the Study Design and Generated Data

The study proceeded in three *in vitro* phases with a fourth *in vivo* validation phase. In the *in vitro* phase, IL-13 transcriptomic effects on a cell type-specific level in human AECs were determined, effects were translated to the secreted proteome, and influences of this altered proteome on mucociliary motion and ciliary beat frequency were determined. In the *in vivo* phase, *in vitro* IL-13 effects were validated using *in vivo* transcriptome data from the nasal airway epithelial brushings of a large cohort of asthmatic and healthy children.

RNA sequencing [RNA-seq]) and limited scope (histology) of these approaches have thus far prevented comprehensive study of cell type-specific responses.

The effects of T2 inflammation on the airway epithelium have been shown to be mediated primarily by T2 cytokines, particularly IL-4, IL-5, and IL-13. For example, human airway epithelial cells (AECs) were recently shown to express a functional IL-5 receptor that, upon stimulation, exhibited differential expression (DE) of >3,000 genes (Barretto et al., 2020). Although these and other regulators of T2 inflammation can play distinctive and collaborative roles, using divergent pathways that orchestrate particular aspects of disease (Bao and Reinhardt, 2015), transgenic overexpression specifically of IL-13 in mice has been shown to be sufficient to recapitulate most of the cardinal features of T2H asthma, occurring both within the airway epithelium and in other tissues (Zhu et al., 1999). Consequently, IL-13 has successfully been used to model the effects of T2 inflammation on the airway epithelium in both *in vivo* mouse models (Chen et al., 2009; Tyner et al., 2006; Zhen et al., 2007) and *in vitro* human AEC cultures (Gerovac and Fregien, 2016; Nicodemus-Johnson et al., 2016; Zhen et al., 2007), revealing some of the key genes, regulators, and cellular shifts brought on by this cytokine. Mouse models have specifically been used to show that binding of IL-13 to its receptor induces activation of SPDEF (Park et al., 2007), leading to the overproduction of mucus and the metaplastic conversion of secretoglobin-secreting club cells into MUC5AC-producing mucous cells (Chen et al., 2009). Supporting translation of this mouse model to human disease, bronchial epithelial expression of MUC5AC is upregulated in T2H asthmatics (Lachowicz-Scroggins et al., 2016; Woodruff et al., 2009), while in mature human mucociliary AEC cultures, IL-13 in-

creases the frequency of MUC5AC⁺ mucus cells at the numerical expense of ciliated cells (Gomperts et al., 2007; Turner et al., 2011). However, many questions regarding the effects of IL-13 on the human airway epithelium remain to be answered, including (1) to what extent metaplastic events or reprogramming of cell fates underlies the observed increases in MUC5AC transcription and mucus secretion, (2) how IL-13 specifically modifies gene expression programs and protein secretions of secretory cell states residing in the healthy airway, and (3) whether changes in behavior and frequency of other cell types (basal, ciliated, club secretory) contribute to IL-13-induced pathology.

To address these gaps in our understanding of T2 airway inflammation, here, we investigate the whole-transcriptome responses to IL-13 of single cells from differentiated human AEC cultures. Using this dataset, we define the transcriptional cell states that populate the unperturbed human airway epithelium and then show how IL-13 stimulation alters these states to create new metaplastic cell populations. We relate these transcriptional effects to IL-13-induced changes to the mucus secretome of the airway epithelium and its accompanying influence on mucociliary function. Finally, we examine the extent to which cellular remodeling and secretory changes observed in response to IL-13 *in vitro* mimics transcriptional reprogramming in children with T2H asthma disease (Figure 1).

RESULTS

Acute IL-13 Stimulation Drives Cellular Remodeling of the Mucociliary Epithelium

We first identified transcriptionally defined cell populations in mature mucociliary air-liquid interface (ALI) cultures of human




Figure 2. Acute IL-13 Stimulation Drives Cellular Remodeling of the Mucociliary Epithelium

(A) Schematic detailing human AEC ALI mucociliary differentiation followed by acute stimulation with IL-13; $n = 2$ human tracheal epithelial cell (HTEC) donors (T71, T72).

(B) t-SNE plot of 1,894 cells depicting nine unsupervised scRNA-seq clusters.

(C) t-SNE plot in (B), with cells colored by characteristic expression of ciliated, secretory, or basal cell gene signatures. See also Figures S1C–S1E.

(D) t-SNE plot in (B), with cells colored by treatment.

(E) Pie charts of differences in cell state proportions within major groups (ciliated, secretory, and basal-secretory) between control and IL-13-stimulated epithelia.


(F) Bar-plot depiction of data in (E).

to represent ciliated cells, on the basis of expression of genes from cilia motility-related Gene Ontology categories (Figures 2C and S1C). Four non-ciliated clusters (c5–c8) expressed genes that mark secretory cell populations (e.g., *SCGB1A1*, *SLPI*) in the airway epithelium, suggesting that these cells carry out secretory functions (Figures 2C and S1D). Although the fifth non-ciliated cluster (c9) exhibited some secretory gene expression, it was most distinguished by expression of basal cell genes (*KRT5* and *TP63*). Moreover, genes differentially expressed in c9 cells were enriched for airway epithelial basal cell genes (hypergeometric test; control cell false discovery rate [FDR] = 1.93×10^{-14} , IL-13 cell FDR = 6.07×10^{-11}) (Hackett et al., 2011), indicating that this population represents basal cells and/or basal cells differentiating into secretory cells (Figures 2C and S1E).

We observed a dramatic secretory cell state “switch” with acute IL-13 treatment (Figure 2D). Namely, although the frequency of secretory cell clusters (c5–c8) remained constant between IL-13 (62%) and control (58%) treatments, secretory cell

AECs and investigated how these populations were affected by acute (48 h) IL-13 stimulation. To do this, we analyzed RNA-seq data from 1,894 single cells (1,025 IL-13-stimulated cells, 869 controls) isolated from mature (day 21) ALI cultures derived from the basal AECs of two tracheal donors (Figures 2A, S1A, and S1B; Table S2). To identify and visualize cell populations, we performed t-distributed stochastic neighbor embedding (t-SNE), followed by the plotting of all cells using the top two t-SNE dimensions and overlaying shared nearest neighborhood (SNN) clustering results. These analyses revealed nine discrete clusters (Figure 2B). Four of the cell clusters (c1–c4) appeared

population membership changed from being overwhelmingly c5 and c7 cluster dominated in the control cultures to being c6 and c8 cluster dominated with IL-13 treatment (Figures 2E and 2F). Specifically, secretory clusters c5 and c7 constituted 35% and 23% of all control culture cells, while these clusters were nearly absent from the IL-13-stimulated cultures (1.4% and 0.1%, respectively; Figures 2E and 2F). In contrast, the c6 and c8 secretory clusters encompassed 38% and 22% of IL-13-treated cells, but altogether only 0.2% of control culture cells. The basal-secretory cluster (c9) contained a mix of control and IL-13-stimulated cells, although t-SNE segregation of IL-13



(legend on next page)

and control cells within the cluster (Figure 2D) indicates reprogramming in this cluster as well (Ordovas-Montanes et al., 2018). Finally, acute IL-13 treatment significantly decreased the percentage of ciliated cells within the cultures, from 38% to 28% ($p < 1 \times 10^{-5}$; Figure 2E). A mix of IL-13 and control cells was observed in each of the four ciliated cell clusters, although clusters c3 and c4 exhibited clear t-SNE partitioning of IL-13 and control cells (Figure 2D). These results illustrate how acute IL-13 stimulation is sufficient to thoroughly transform cellular composition of the mature airway epithelium.

Normal Defense and Mucus Secretory Cells Are Reprogrammed by IL-13 into a Distinct Pathologic Mucus Secretory State

Studies in mice have established that IL-13 transforms the epithelium through a metaplastic rather than a hyperplastic process (Chen et al., 2009). In support of a metaplastic basis to the observed secretory cell “switch,” we found that neither proliferation nor apoptosis increased with IL-13 stimulation (Figure S2A). In mice, the IL-13-induced generation of mucin 5ac (MUC5AC⁺) goblet cells occurs through metaplasia of secretoglobin 1a1 (SCGB1A1⁺) club cells (Evans et al., 2004). Investigating whether a similar process might underlie the secretory cell switch in humans, we stained control and IL-13-stimulated cultures for both MUC5AC and SCGB1A1 protein. In the control cultures, we found that among cells staining positive for one or both markers, 79% were exclusively SCGB1A1⁺, 15% were exclusively MUC5AC⁺, and only 5.8% were double-positive (Figures 3A and S2B). In contrast, after acute IL-13, only 20% of cells were exclusively SCGB1A1⁺, while 48% were exclusively MUC5AC⁺ (3.2-fold increase), and 32% were double-positive (5.6-fold increase), suggesting that SCGB1A1⁺ cells are a source of MUC5AC⁺ cells (Chen et al., 2009; Evans et al., 2004; Figures 3A and S2B). A 2.2-fold reduction of *SCGB1A1* expression and a 1.5-fold increase of *MUC5AC* in the two IL-13 treatment-dominant secretory populations (c6 and c8) compared with the control-dominant populations (c5 and c7) further support this SCGB1A1⁺ to MUC5AC⁺ transition.

We thus aimed to investigate the genes and pathways underlying IL-13-induced metaplasia of secretory cells in our dataset. However, prior to doing this, we needed to (1) identify which baseline populations transition into which IL-13 populations and (2) characterize the role of these secretory populations in

the airway epithelium. First, because we observed four secretory cell populations, two consisting of SCGB1A1⁺ control cells and two consisting of MUC5AC⁺ IL-13 cells, we reasoned that two distinct baseline secretory cell populations each transitioned into one of the corresponding IL-13 populations. To match analogous baseline and IL-13-induced populations, we compared gene signatures among them and found highly concordant signatures between populations c5 (control) and c6 (IL-13) and between populations c7 (control) and c8 (IL-13), strongly suggesting that IL-13 stimulation caused c5 to transition into c6 and c7 to transition into c8 (Figures S2C and S2D).

Having identified analogous baseline and IL-13 populations, we next characterized the shared function of these population pairs. To do this, we first performed pathway analysis on the defining genes of c5/c6 secretory cells when compared with c7/c8 cells, which resulted in enriched terms related to airway detoxification, protein secretion, and metabolism (Figure 3B). Active protein secretion of c5/c6 cells was supported by enrichments for extracellular vesicular exosome, transmembrane transport, and ATPase activity. Moreover, these populations more highly expressed defense genes, such as *SCGB1A1*, *WFDC2*, *LYN*, *SLPI*, and *B2M*, as well as genes related to the glutathione-derivative biosynthetic process/metabolism of xenobiotics (e.g., *GSTP1*, *MGST1*) and detoxification of reactive oxygen species, strongly suggesting that c5/c6 cells are airway defense-secretory cells, similar to the club cell in mice.

We similarly performed pathway analysis on the genes defining c7/c8 cells compared to c5/c6 cells, resulting in enrichments for gene groups involved in MAPK, NOTCH, and EGFR signaling, all of which have been implicated in mucin production and secretion, as well as in the folding (e.g., trans-Golgi network), O-linked glycosylation, and transport and storage of mucins (Figure 3B). Examination of gel-forming mucin expression (*MUC5B* and *MUC5AC*) was impeded by poor detection of these transcripts with our single-cell RNA-seq [scRNA-seq] method, despite immunocytochemistry revealing an abundance of MUC5B⁺ cells (Figure S2E) or MUC5AC⁺ cells (Figures 3A and S2B) in control or IL-13-induced cultures, respectively. Notably, we did find that the two most common transmembrane mucins (*MUC4* and *MUC16*) were both more highly expressed in these clusters. Together these data suggest that c7/c8 cells are more specialized for mucin production and mucus secretion than are c5/c6 cells.

Figure 3. Normal Defense and Mucus Secretory Cells Are Reprogrammed by IL-13 into a Distinct Pathologic Mucus Secretory State

(A) Immunofluorescence (IF) labeling of ALI-differentiated human AEC cultures in top-down (top) and side (bottom) views show control cultures (left) dominated by SCGB1A1⁺ (green) and MUC5AC⁻ (red) cells transformed into cultures (right) with prominent co-staining (yellow) after acute IL-13. $n = 3$ HTEC donors (T73, T76, T79); scale bar, 30 μ m; DAPI nuclei labeling (blue).

(B) Heatmap shows shared functions between pairs of control and IL-13-dominant secretory populations (c5/c6, c7/c8, and c9-control/c9-IL-13). Mean scaled expression of population-defining DEGs within enriched functionally annotated sets is shown.

(C) Scatterplot compares responses to IL-13 in defense (y) and mucus (x) secretory cells. Points, expression log fold changes with IL-13; filled, differentially expressed in both populations; unfilled, differentially expressed in one population; colored, belonging to specified function categories.

(D) TFs whose expression significantly changes across a pseudotime trajectory transitioning from baseline to IL-13-stimulated cell states. Left: TFs increasing (top) or decreasing (bottom) across pseudotime. Right: scaled normalized expression (points) and smoothed trends (lines) for exemplar TFs across pseudotime-ordered cells. Point color, population as in (B); line color, defense-secretory (black), mucus-secretory (red).

(E) Dot plots show shifts in level (dot color) and ubiquity (dot size) of expression for genes “activated” (top) or “suppressed” (bottom) by IL-13 in one or both secretory populations. Functional groups as in (C). Gene label font color: gold, defense; brown, mucus (population with strongest effect is shown). Same direction responses in both population pairs are indicated by asterisk (significant) or point (not significant). See also Figure S2.

Having characterized these secretory cell populations, we next examined how gene expression, and thus function, of these defense and mucus secretory populations were altered by IL-13. We performed DE analysis between control and IL-13-treated populations for defense secretory (c5 versus c6) and mucus secretory cells (c7 versus c8). We identified 396 and 535 differentially expressed genes (DEGs) in defense and mucus secretory cells, respectively. A shared IL-13 response between the two cell types was evident from 208 overlapping DEGs, which exhibited a strong correlation in expression fold changes between cell types ($R^2 = 0.86$; Figure 3C). This group of shared IL-13-response genes was enriched for those DEGs with the largest fold changes and included genes known to characterize both IL-13 stimulation of the airway epithelium *in vitro* and T2 inflammation of the airway epithelium *in vivo*, such as *CDH26*, *DPP4*, *FCGBP*, *MUC5AC*, and *POSTN*. This shared IL-13 response also included upregulation of genes involved in mucin production and secretion (e.g., ion transport ATPases, glycosylation genes, mucins and mucin-related genes; Figure 3C) and downregulation of genes involved in airway defense (Figure 3C), indicating that the mucus/defense-secretory balance in the epithelium was significantly shifted in both secretory cell types. To identify gene regulators of these shared IL-13-mediated transcriptional changes, we constructed a pseudotime trajectory of IL-13 stimulation using all control and IL-13-secretory cells (Figure S2F). In addition to observing increased expression of *SPDEF* across pseudotime, we identified multiple novel transcription factors (TFs) that significantly increased and/or decreased expression across pseudotime, including many known regulators of Wnt signaling (e.g., repressors [*KLF4*, *NFAT5*, *TCF7L1*] and activators [*LRRFIP2*, *SOX4*, *FHL2*, and *EPAS1*]; Figure 3D), suggesting that Wnt signaling may help modulate the IL-13 response in secretory cells.

Interestingly, the vast majority of IL-13 DEGs were markers neither of baseline mucus secretory cells (89%) nor of defense secretory cells (95%). “Activated” genes (those not among cell type signature genes) included a majority of the shared DEGs highlighted in Figure 3C relating to mucin production and secretion (Figure 3E), suggesting that IL-13 has significantly altered the manner in which mucus secretory cells produce and secrete mucus and also that many of these emergent pro-mucus pathways are similarly activated in defense-focused secretory cells. For example, a set of glycosylation genes were activated, likely modifying how mucins are being glycosylated, while activation of ion transport ATPases and solute carriers signals a modification in how air surface liquid hydration is maintained (Figure 3E). Additionally, IL-13-induced expression of the mucin-interacting proteins *ITLN1* and *FCGBP* likely indicates alterations to the physical properties of IL-13-stimulated mucus (Figure 3E). Induction of this novel mucus-secretory program coincided with suppression of the two most abundant transmembrane mucins at baseline (*MUC4* and *MUC16*) and the enhanced expression of *MUC5AC*, in line with histology (Figure 3A). Acquisition of this new IL-13 mucus-secretory function was accompanied by a loss of airway defense function in both the mucus and defense-secretory populations (e.g., antioxidants, defensins, and immune cell chemoattractants; Figure 3E). Together, these results show that IL-13 induces tran-

scriptional reprogramming of secretory cells through a metaplastic process that converts secretory populations focused on airway defense or healthy mucus production into distinct states focused on production of a MUC5AC-enriched pathological mucus.

Ciliated Cells Acquire Secretory Cell Expression Patterns with IL-13 Stimulation at the Expense of Ciliogenic and Innate Immunity Functions

As with the secretory populations, we first determined the distinct nature of four ciliated cell clusters using DE analysis. The c1 ciliated cell population was most distinguished by high expression of centriole biogenesis genes, suggesting that these cells were in an early stage of multiciliogenesis (Ruiz Garcia et al., 2019; Figure 4A). Marker genes for c2 were enriched in gene groups involved in the endomembrane system, which may contribute to development of the ciliary membrane (Ishikawa and Marshall, 2011), c3 exhibited upregulation of genes relating to ciliary motility and axoneme generation, and c4 appeared to be particularly focused on intraflagellar transport, while also exhibiting a distinct immune, metabolic, and secretory profile (Figure 4A).

To characterize IL-13 effects on ciliated cells, we carried out DE analysis between control and IL-13 cells for all ciliated populations combined, yielding 201 upregulated DEGs and 136 downregulated DEGs. Interestingly, we found that 24 of the top 25 IL-13 DEGs in ciliated cells were also DEGs in secretory cells, including T2 biomarkers, *ALOX15*, *CCL26*, *CDH26*, and *SERPINB4*. Furthermore, the expression fold changes for ciliated and secretory IL-13 DEGs were highly correlated ($R^2 = 0.44$; Figure 4B), with upregulation of many of the same ion transport ATPases (*ATP1A1*, *ATP1B1*), solute carriers (*SLC9B2*, *SLC9A9*), and endopeptidase inhibitors (*CAPN14*, *CSTA*) and downregulation of many of the same innate immunity-related genes, including *SCGB1A1* (Figure 4C), *ABCA13*, *CYP2B7P*, *WFDC2*, antioxidants such as *GLUL*, *CP*, *GSTA1/2*, and defensins such as *S100A2* and *S100A8* (Figure 4B). Additionally, while secretion-related genes were upregulated with IL-13, many components of the expansive ciliated cell transcription program were downregulated, including ciliary assembly and motility genes (Figures 4B and 4C). Although *MUC5AC* expression was activated in ciliated cells, they failed to contain MUC5AC protein. Moreover, many prominent IL-13-secretory cell DEGs thought to be directly involved in mucin formation and structure (e.g., glycosylation genes, *FCGBP*, *ITLN1*, and *SCIN*) were not induced by IL-13 in ciliated cells. This suggests that although the normal ciliogenesis expression program is blocked and an IL-13-secretory program is transcriptionally induced in ciliated cells, these cells are not actively secreting mucus.

Despite many similarities in the IL-13 responses of ciliated and secretory cells, activated TFs in ciliated cells included several NF- κ B-mediated pro-inflammatory regulators (*PIR*, *POU2AF1*, *RUNX1*, *XBP1*) that were not significantly upregulated in secretory cells (Figure 4D), suggesting that inflammatory signaling was particularly activated in ciliated cells. This may be triggered by enhanced endoplasmic reticulum (ER) stress, resulting from the induction of a secretory transcriptional program in these




Figure 4. Ciliated Cells Acquire Secretory Cell Expression Patterns with IL-13 at the Expense of Ciliogenic and Innate Immunity Functions

(A) Heatmap shows expression of functionally annotated gene groups distinguishing four ciliated cell populations. Mean scaled expression of population-defining DEGs within enriched functionally annotated sets is shown.

(B) Scatterplot compares ciliated and secretory (defense + mucus) cell responses to IL-13. Points, expression log fold changes with IL-13; filled, differentially expressed in both populations; unfilled, differentially expressed in one population; colored, belonging to specified function categories.

(C) Violin plots show expression in ciliated cells of key genes (top row) and mean expression of sets of genes up or downregulated with IL-13 that belong to enriched pathways (middle and bottom rows). FDRs are based on DE analysis; p values (p) are based on one-sided Wilcoxon tests.

(D) Violin plots of expression of TFs up and downregulated with IL-13 in ciliated cells. Numbers below plots give FDRs based on DE analysis (where “not sig” denotes differences that were not significant).

cells. TFs downregulated by IL-13 in ciliated cells (Figure 4D) included *RFX3*, an important regulator of ciliogenesis.

Collectively, these results show that ciliated cells are reprogrammed by IL-13 to downregulate ciliogenesis and innate immunity functions, while gaining secretory function associated with inflammation.

Chronic IL-13 Stimulation Brings to Completion Metaplasia and Promotes ER Stress and Interferon Immune Responses

Although acute stimulation was able to model the initial transcriptional effects of IL-13 on the naive airway epithelium, we also generated a longer term stimulation model to identify

changes in the T2H asthmatic airway that are dependent on more persistent IL-13. Specifically, we applied IL-13 daily for 11 days (Figure 5A) to mucociliary cultures grown from the same two tracheal donors used in the acute experiment. We then analyzed RNA-seq data generated for 789 single cells derived from these cultures.

Using an approach similar to our acute dataset analysis, we inferred eight cell populations (Figure 5B), with marker expression revealing four secretory and four ciliated cell clusters (Figure S3A). Secretory cell clusters included both defense and mucus types observed in the 48 h data, one of each specific to control and IL-13 cultures (Figure 5B), suggesting that the same secretory cell “switch” observed in the 48 h dataset also occurred with chronic stimulation (Figures S3B and S3C). Supporting this, of the mucus secretory genes activated or suppressed with acute IL-13 in both defense and mucus secretory cells, 91% or 75% of these were also upregulated or downregulated, respectively, in one or both of the secretory populations after chronic stimulation. Similarly, IL-13 responses in ciliated cells were broadly concordant between experiments, with 84% or 46% of the top 50 up- or downregulated DEGs in acutely stimulated ciliated cells being also up- or downregulated, respectively, in chronically stimulated ciliated cells.

Although the chronic IL-13 response contained many of the same transcriptional shifts observed with acute stimulation, fold changes in expression of IL-13-response genes shared between the two datasets tended to be more extreme with chronic stimulation, regardless of the direction of change or cell type (Figure 5C). For example, downregulation of *SCGB1A1* and upregulation of *MUC5AC* in both secretory and ciliated cells were stronger with chronic than with acute stimulation (Figure 5C). This more extreme chronic response extended to the protein level, with the *SCGB1A1*/*MUC5AC* double-positive cells induced with acute IL-13 (Figure 3A) becoming highly positive for *MUC5AC* and negative for *SCGB1A1* after 11 days of stimulation (Figure 5D). Furthermore, we found the ratio of defense to mucus secretory cells to be reduced from 3:1 in control cultures to near 1:1 with chronic IL-13 (Figure S3D). This shift is consistent with defense secretory cells, which gained new mucus secretory properties with acute IL-13, eventually making a full transition to the IL-13 mucus secretory state after prolonged inflammation. Enrichment analysis on the basis of genes exhibiting a greater response with chronic, compared with acute IL-13, revealed that innate immunity genes suppressed with acute IL-13 in both ciliated and secretory cells were even further downregulated after 11 days (Figure 5E). Overall, these data show that prolonged IL-13 stimulation exacerbates many of the expression changes initiated under acute IL-13.

Additionally, some responses to IL-13 were observed only after chronic stimulation. For example, DEGs annotated by enriched terms related to secretion (e.g., salivary secretion in ciliated cells and ER to Golgi transport in secretory cells) were activated only after 11 days of IL-13 (Figure 5F), accompanied by the chronic-dependent upregulation of *AGR2* and *ERO1A* in both secretory and ciliated cells, two known markers of ER stress induced by mucin production. Also indicative of an ER

stress response being uniquely activated with chronic stimulation was the chronic-dependent induction of a suite of type I interferon-induced genes and their regulators (e.g., *IFI27*, *IFITM2*, *IFITM3*, *IFI6*, *IFIH1*, *IRF6*, and *DDX58*) as well as inflammatory genes (e.g., *HLA-DRA*, *HLA-DRB1*, *HLA-A/B/C*), most strongly in ciliated cells, but also in secretory cells (Figure 5F), suggesting that there is a unique burden of mucin and secretory-related proteins with long-term IL-13, culminating in interferon-related inflammation.

The IL-13-Induced Epithelial Secretome Exhibits a Highly Modified Mucus and Weakened Innate Immunity, Consistent with Transcriptomic Shifts

Our scRNA-seq data suggested that defensive secretory function is lost and new mucus-secretory function is acquired in airway epithelia chronically stimulated with IL-13. To investigate whether these transcriptomic changes are also observed at the level of secreted proteins, we collected apical secretions from paired ALI cultures of bronchial epithelia from 14 donors, after 10 days of mock or IL-13 stimulation, for use in mass spectrometry-based proteomic analysis. We analyzed the soluble component of these secretions in all subjects ($n = 14$) and the mucus solids in a subset ($n = 6$). In the soluble fraction, 980 unique proteins were detected across samples, with an average of 272 unique proteins per sample (results for the mucus fraction were broadly similar; see Figures S4A–S4C). We tested whether protein levels differed with IL-13 stimulation, identifying 39 upregulated and 58 downregulated proteins in the soluble fraction (Figure 6A), which exhibited log fold changes that were remarkably correlated with those from the acute ($R^2 = 0.5$) and chronic ($R^2 = 0.4$) transcriptome experiments (Figures S4D and S4E). Of particular interest, we found that the two most prominent gel-forming mucins in the human airway, *MUC5AC* and *MUC5B*, were strongly upregulated (1.68-fold) and downregulated (3.85-fold), respectively, leading to a strong increase in their average ratio (5.02-fold) (Figure 6B). Additionally, we found that *MUC2*, thought to be primarily a gut gel-forming mucin, was induced in four of the IL-13 cultures, while not present in any control cultures. At the same time, transmembrane mucins, *MUC4* (2.36-fold) and *MUC16* (10.22-fold) were downregulated (Figure 6C). These mucins can be liberated from the airway surface by cleavage and have previously been observed in human airway mucus. Relatedly, we observed strong upregulation of mucin domain-containing protein, *FCGBP*, and mucin crosslinkers, *ITLN1* and *ITLN2*, which were absent in all controls. Upregulated proteins were also enriched for salivary secretion and ER stress response, consistent with an enhanced ER load due to both quantitative and qualitative changes in mucin secretory activity under IL-13.

In contrast, IL-13 downregulated many of the most prominent and highly secreted defense proteins in the airway epithelium, including *SCGB1A1* (2.31-fold), *BPIFA1* (23.15-fold), and *LTF* (27.55-fold). Furthermore, enriched terms for downregulated proteins encompassed those related to detoxification, the innate immune system, and antimicrobial humoral response, revealing a broad loss in normal defensive protein secretion within the IL-13-stimulated airway.





Figure 5. Chronic IL-13 Completes Epithelium-wide Metaplasia and Promotes Both ER Stress and Interferon Responses in Ciliated Cells

(A) Schematic detailing human AEC ALI mucociliary differentiation followed by chronic stimulation with IL-13 of cells; n = 2 HTEC donors (T71, T72).
 (B) t-SNE plot overlaying cell clusters (left) or cell treatment (right) for 789 cells from experiment in (A).
 (C) Density plots show probability distribution (on the basis of a kernel density function) of shifts in log fold change between acute and chronic datasets for genes up (left) or downregulated (right) with IL-13 in ciliated (top) or secretory (mucus + defense) cells (bottom). All shifts significant with t test p values < 0.05. Bar plots compare log fold changes in *MUC5AC* and *SCGB1A1* between acute and chronic IL-13.
 (D) Immunofluorescence (IF) labeling of ALI-differentiated human AEC cultures in top-down (top) and side (bottom) views show control cultures (left) dominated by *SCGB1A1*⁺/*MUC5AC*⁻ cells transformed by chronic IL-13 into *SCGB1A1*⁻/*MUC5AC*⁺-dominated cultures (right). Co-staining (yellow); DAPI nuclei (blue); scale bar, 30 μ m; n = 3 HTEC donors (same as in Figure 3A).
 (E) Boxplots show mean log fold change of IL-13 markers and innate immunity genes responding significantly more strongly with chronic than acute IL-13. p values (p) are based on one-sided Wilcoxon tests.
 (F) Boxplots show mean log fold change of enriched annotated gene sets composed of genes exhibiting significantly stronger responses with chronic compared with acute IL-13. p values (p) are based on one-sided Wilcoxon tests.
 See also Figure S3.



(legend on next page)

IL-13-Modified Mucus Slows Ciliary Beat Frequency and Arrests Mucociliary Transport

We expected that dramatic changes in both the amount and type of mucins, mucus structural proteins, and other products secreted under IL-13 would modify properties of mucociliary movement in these cultures. Video examination of mucociliary movement through fluorescent bead tracking revealed its near complete loss in cultures stimulated chronically with IL-13 (Video S1). This loss could result from dysfunction or reduction of cilia (Laoukili et al., 2001) and/or to changes in mucus properties, the latter of which was suggested by our proteomic results. To investigate this, we used differential dynamic microscopy (DDM) and particle image velocimetry (PIV) to measure ciliary beat frequency (CBF) from top-down and profile imaging, respectively, of mock and IL-13-stimulated cultures, before and after application of apical washes. These disulfide bond-reducing washes were meant to both hydrate and remove mucus and break down its structure, increasing fluidity. High-speed profile videos of ciliary beating show that although ciliated cells remained able to beat with IL-13 stimulation, this beating was not productive in generating movement of the mucus layer in unwashed cultures (Video S2). Moreover, analysis of top-down CBF data revealed a significant decrease in mean CBF (2.15 Hz) with IL-13 in unwashed cultures, while washing resulted in partial restoration in CBF (1.08 Hz recovery; Figure 6D; Table S1) and mucociliary movement (Video S2). CBF measures based on profile imaging validated these results, showing an even more pronounced reduction in CBF with IL-13 in the unwashed cultures (4.68 Hz) and an almost complete restoration to baseline CBF after washing (Figure 6E). These results illustrate how deceleration of ciliary beating and arrest of mucociliary motion with chronic IL-13 stimulation are strongly related to modified physical properties of mucus generated by these cultures.

The Airway Epithelium of T2H Children Exhibits Expression Changes Indicative of an IL-13-Remodeled Epithelium with a Modified Mucus Secretome

Finally, we sought to determine the extent to which IL-13-induced changes to cell composition, gene expression, and protein secretome in AEC cultures accurately modeled characteristics of the airway epithelium in T2H subjects. To do this, we generated whole-transcriptome data from nasal AEC brushings of 695 children (441 asthmatics and 254 healthy controls) belonging to the Genes-Environments & Admixture in Latino Asthmatics (GALA II) cohort. We performed co-expression-based gene network analysis to identify a network of T2 inflammation to be used in the classification of subjects into T2H and

T2-low (T2L) groups. This analysis yielded a network containing 47 genes highly enriched in well-established epithelial markers of T2 airway inflammation (e.g., *POSTN*, *CLCA1*, *IL1RL1*, *DPP4*). Moreover, expression of this network exhibited a highly significant correlation with levels of both blood eosinophil (Pearson's $r = 0.56$, $p = 4.4 \times 10^{-59}$) and IgE (Pearson's $r = 0.54$, $p = 1.3 \times 10^{-48}$), two strong biomarkers of T2 inflammation. Hierarchical clustering of subjects on the basis of expression of these T2 network genes segregated them into two groups exhibiting high (T2H) or low (T2L) expression of these genes, respectively (Figure 7A). We found remarkable concordance between *in vitro* IL-13 responses of the airway epithelium and the genes defining the *in vivo* T2H airway epithelium (Figures 7A and S5). For example, the same endopeptidase inhibitors, pro-inflammatory genes, and genes related to mucus production and secretion induced by IL-13 were upregulated in T2H subjects, whereas, the same IL-13 downregulated genes, including those related to innate immunity and ciliary function, were also strongly reduced in T2H subjects (Figure 7A).

Importantly, this concordance extended to the response of genes in the epithelial secretome. We found mean expression of genes encoding IL-13 up- and downregulated secreted proteins to be highly upregulated ($p = 2.6 \times 10^{-109}$) and downregulated ($p = 2.4 \times 10^{-14}$), respectively, among T2H subjects (Figure 7B). Among these, the gel-forming mucins *MUC5AC* and *MUC5B* exhibited a 1.61-fold ($p = 1.9 \times 10^{-32}$) increase and 2.42-fold ($p = 3.0 \times 10^{-17}$) decrease, respectively, in T2H subjects, resulting in a 4.03-fold average shift in the *MUC5AC/MUC5B* ratio ($p = 1.4 \times 10^{-28}$) (Figure 7C). The rarer gel-forming airway mucin *MUC2* was similarly upregulated in T2H subjects (2.11-fold, $p = 4.9 \times 10^{-33}$). In contrast, markers of healthy airway function, such as *FOXJ1*, a master regulator of ciliogenesis, and the secretory defense marker, *SCGB1A1*, were strongly downregulated in T2H subjects (Figure 7C). Taken together, these results demonstrate that the cellular remodeling and changes to both the epithelial secretome and properties of mucus identified by our IL-13 model faithfully capture transformation of the *in vivo* airway epithelium of T2H children (Figure 7D).

DISCUSSION

Leveraging the resolution and scope of scRNA-seq, we have presented a more nuanced view into the effects of IL-13 on the airway epithelium. We find that rather than simply increasing secretion of mucus or *MUC5AC* protein in mucus secretory cells, IL-13 transcriptionally and functionally transforms the very

Figure 6. The IL-13-Stimulated Epithelium Downregulates Secretion of Innate Defensive Proteins and Activates Secretion of Mucus-Related Proteins, while Decelerating Ciliary Beat Frequency and Mucociliary Transport

- (A) Heatmap of normalized spectral counts for soluble apical secretome proteins significantly up- or downregulated with IL-13; $n = 14$ paired HBEC cultures.
 (B) Boxplots compare soluble apical secretome protein abundance between control and IL-13-stimulated samples for proteins or enriched terms upregulated with IL-13. FDRs are based on DE analysis; p values are based on one-sided Wilcoxon tests.
 (C) Same as (B) but based on proteins downregulated with IL-13.
 (D) Density plots and boxplots (insets) show distributional shift in CBF with chronic IL-13 on the basis of top-down imaging before (left) and after (right) apical washing. Specified shifts and p values from a linear mixed model; outliers excluded from boxplots; $n = 6$ paired HBEC cultures.
 (E) Same as (D) but based on profile imaging; $n = 2$ paired HTEC cultures.
 See also Figure S4 and Videos S1 and S2.




Figure 7. IL-13-Activated Expression and Secretion Responses of the Airway Epithelium Are Mirrored by Changes in the Airway Epithelium of T2H Children

(A) Heatmap shows functional gene groups responding to IL-13 *in vitro* are also differentially regulated between T2L and T2H children *in vivo*; n = 695. Genes and functional groups are the same as in Figures 3C, 4B, S4D, and S4E. Samples are sorted from left to right by increasing T2 inflammation signatures.

(B) Boxplots show how average expression of genes coding for proteins up- or downregulated by IL-13 in the soluble apical secretome shows similar trends in T2H individuals.

(C) Boxplots compare expression of key AEC genes between T2L and T2H donors.

(D) Schematic summarizing metaplastic and dysregulatory transformation of the T2L human airway epithelium (top) under T2 inflammation (bottom), on the basis of both our *in vitro* IL-13 model and transcriptomes of a large *in vivo* cohort.

See also Figure S5.

nature of all cell types in the epithelium. This metaplastic epithelium, characterized by a distinct cellular composition and transcriptional programming, produces pathologic secretions that contain new mucus constituents while being bereft of homeostatic innate defense proteins, results that are consistent with the fact that this mechanism evolved to combat complex and potentially fatal parasitic infections. Translating this work to the *in vivo* human airway epithelium, we find strong evidence that these mechanisms operate in the airway of children with T2H asthma. Our results not only provide insight into T2H asthma pathobiology, which can be harnessed for development of targeted disease therapies, but also illustrate the remarkable plasticity of the airway epithelium in response to stimulus.

By identifying cell types among human AECs and their responses to IL-13 with single-cell resolution, we have shown that T2-induced metaplastic events that occur in mice (Chen et al., 2009; Evans et al., 2004) have an analog in humans. However, in contrast to one SCGB1A1⁺ cell population reported in mice, we observed two distinct secretory populations expressing SCGB1A1 at baseline, one characteristic of a club defense cell and the other more focused on mucus production. We show that IL-13 initiated a metaplastic process in both cell populations, culminating in a new type of MUC5AC⁺ mucus secretory cell. These IL-13 mucus secretory cells exhibited extensive reprogramming, which includes activation of a battery of new glycosylation genes, solute carriers, and mucin-interacting proteins. Importantly, this transcriptional divergence generated a mucus layer that arrested mucociliary motion and slowed CBF in a mucus-dependent fashion. Although prior work has suggested that increases in MUC5AC protein and the MUC5AC-mediated tethering of mucus are the source of depressed mucociliary movement driven by IL-13 (Bonser and Erle, 2017), we observed 39 IL-13-induced secreted proteins that might also play a role. Indeed, proteins exclusive to the IL-13 condition included the gut gel-forming mucin (MUC2), the mucin-interacting FCGBP, and lectin proteins that may mediate mucin cross-linking (ITLN1 and ITLN2). These and other mucus-related proteins, genes, and pathways that underlie production and secretion of IL-13-modified mucus by metaplastic secretory cells may present excellent targets for the specific disruption of these cells and their accompanying mucus.

Although there is general consensus that a ciliated cell cannot transdifferentiate into a mucus secretory cell, two studies have reported that ciliated cells express MUC5AC with IL-13 (Turner et al., 2011; Tyner et al., 2006). Investigating this at a single-cell transcriptome level, we find that much of the IL-13-induced mucus secretory expression program is remarkably acquired by ciliated cells, including MUC5AC. Moreover, although we failed to observe MUC5AC protein in ciliated cells, their strong ER stress response under IL-13 suggests to us a hypothesis that the particularly strong interferon response in ciliated cells induced by chronic IL-13 results from the stress involved in these cells trying to generate functional mucin proteins that they are not fully equipped to manufacture. This interferon response adds to the T2 inflammatory environment and may eventually lead to ciliated cell death, as supported by a decrease in ciliated cell frequency with IL-13. Moreover, surviving ciliated cells downregulate ciliogenesis genes, likely

compromising function, and we confirmed that this ciliated cell dysfunction occurs in the airway of T2H compared with T2L children, on the basis of transcriptional shifts. The interferon response to chronic IL-13 is particularly interesting given previous studies finding a suppression of interferons and interferon-stimulated genes when the T2 inflamed airway epithelium is subjected to virus, which is thought to enhance susceptibility to virus infections in those with asthma or COPD (Chen et al., 2014; Contoli et al., 2015; Korfhagen et al., 2012; Wark et al., 2005). It is possible that under chronic T2 inflammation, antiviral responses that are initially downregulated by T2 pathways, as a way to limit type 1 inflammation, may be reinstated if cells become sufficiently stressed because of extended mucin protein burden.

We also found an underappreciated pan-epithelial loss of innate airway defenses due to IL-13, affecting all cell types and including many secreted antimicrobial and detoxification proteins and genes. Although previous research has shown that IL-13 can limit some pathways of innate defense in the human AECs (Beisswenger et al., 2006; Chen et al., 2014; Wu et al., 2012), our study defines the transcriptome-wide genes involved and demonstrates the pervasiveness of this loss of function across all cell types. Moreover, we confirmed that MUC5B, critical for antibacterial defenses in mice (Livraghi-Bu-trico et al., 2017; Roy et al., 2014), was transcriptionally downregulated in T2H children, along with an assortment of other innate defense-related genes. Furthermore, we show that not only did IL-13 reduce defense expression, but also the frequency of defense-focused secretory cells in the airway epithelium, when applied chronically. Taken together, this reduction in innate airway defense and loss of ciliary function, when coupled with an airway wash with adhesive MUC5AC⁺ mucus, provides a mechanistic explanation for the increased vulnerability of allergic asthmatics to respiratory infections that require antibiotics and exacerbate disease (Juhn, 2014; Woehlk et al., 2018).

Although our scRNA-seq analysis has enabled us to study the cell type-specific nature of IL-13-induced metaplasia in the airway epithelium, additional sampling of both more subjects and more cells would enable us to extend this analysis further into cell types that we were unable to detect with our sampling, including different types of basal cells as well as rare epithelial cell types that are particularly relevant to disease. Furthermore, *in vivo* scRNA-seq data, such as from subjects in the GALA II asthma cohort, would be an incredibly powerful tool for validating that the cell type-specific transformations we observe *in vitro* translate into cell type-specific effects of T2 inflammation.

T2 cytokine inhibitors have recently become available, enjoying some success in reducing exacerbation rates (Bousquet et al., 2005; Castro et al., 2015; Nair et al., 2017), but their limited ability to improve lung function (Liu et al., 2013; Noonan et al., 2013; Russell et al., 2018) suggests either that not all core T2 inflammatory pathways are blocked by these drugs or that the T2 airway epithelium can be locked into a metaplastic state, despite blockade of the T2 stimulus. Thus, treating T2 airway disease may ultimately require us to “reverse-remodel” the airway epithelium. As such, improved

therapeutics will likely target epithelial pathways controlling production and release of T2 cytokine-inducing alarmins such as TSLP, IL-33, and IL-25, while reversing the meta-plastic events underlying mucus obstruction and loss of immunity inherent to disease. Epithelial responses to other environmental toxicants and pathogens that underlie airway disease, such as cigarette smoke, pollution, and viruses, may similarly involve widespread remodeling of the airway epithelium. Elucidation of how the epithelium is remodeled in asthma and other chronic obstruction lung diseases may hold the key to development of new therapies that provide lasting improvements for these patients.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
 - Lead Contact
 - Materials Availability
 - Data and Code Availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
 - Human tracheal samples
 - Human bronchial samples
 - GALA II nasal airway epithelial samples
 - Air-liquid interface *in vitro* model
- **METHOD DETAILS**
 - ALI culture differentiation and IL-13 stimulation - HTEC stimulation experiments for scRNA-seq
 - ALI culture differentiation and IL-13 stimulation - HBEC stimulation experiments for proteomic and functional assays
 - Harvesting of cells for scRNA-seq
 - Single cell RNA isolation and sequencing
 - Immunofluorescence microscopy
 - Fluorescence *in situ* hybridization (RNAScope)
 - Proteomic sample preparation
 - Mass spectrometry
 - Top-down imaging and measurement of ciliary beat frequency
 - Profile imaging of ciliary beating pattern
 - Mucociliary movement analysis using particle tracking
 - RNA extraction, library preparation, and sequencing for GALA II nasal epithelial brushings
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
 - Pre-processing of scRNA-seq data
 - Pre-processing of bulk RNA-seq data
 - Clustering and visualization of scRNA-seq data
 - Plotting expression across cells
 - Differential gene expression analysis
 - Functional enrichment analysis
 - Lineage trajectories
 - Differential protein abundance
 - Analyzing ciliary beat frequency
 - Normalization of bulk RNA-seq data
 - Assignment to type 2-high/low status

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2020.107872>.

ACKNOWLEDGMENTS

This work was supported by NIH grants R01 HL135156, R01 MD010443, R01 HL128439, P01 HL132821, U01 HL138626, the National Jewish Health REGEN Program, and the European Union (EU)-European Research Council (ERC) CoG HydroSync grant.

AUTHOR CONTRIBUTIONS

Conceptualization, N.D.J., J.L.E., E.G.B., and M.A.S.; Methodology, N.D.J., J.L.E., M.C., L.F., K.C.G., S.P.S., and M.A.S.; Software, N.D.J., M.C., L.F., and S.P.S.; Validation, N.D.J., J.L.E., K.C.G., and M.A.S.; Formal Analysis, N.D.J. and S.P.S.; Investigation, J.L.E., M.C., L.F., K.C.G., C.L.R., R.P., M.A., J.G., C.M., and N.R.; Resources, J.L.E., K.C.G., C.L.R., R.P., M.A., J.G., C.M., C.E., S.S.O., J.R.-S., P.C., N.R., E.G.B., and M.A.S.; Writing – Original Draft, N.D.J., J.L.E., K.C.G., and M.A.S.; Writing – Review & Editing, N.D.J., J.L.E., and M.A.S.; Visualization, N.D.J., J.L.E., and K.C.G.; Funding Acquisition, E.G.B., M.A.S., and P.C.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: March 12, 2020

Revised: May 14, 2020

Accepted: June 15, 2020

Published: July 7, 2020

REFERENCES

- Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* *31*, 166–169.
- Bao, K., and Reinhardt, R.L. (2015). The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. *Cytokine* *75*, 25–37.
- Barceló, B., Pons, J., Fuster, A., Sauleda, J., Noguera, A., Ferrer, J.M., and Agustí, A.G.N. (2006). Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. *Clin. Exp. Immunol.* *145*, 474–479.
- Barretto, K.T., Brockman-Schneider, R.A., Kuipers, I., Basnet, S., Bochkov, Y.A., Altman, M.C., Jarjour, N.N., Gern, J.E., and Esnault, S. (2020). Human airway epithelial cells express a functional IL-5 receptor. *Allergy*.
- Beisswenger, C., Kandler, K., Hess, C., Garn, H., Felgentreff, K., Wegmann, M., Renz, H., Vogelmeier, C., and Bals, R. (2006). Allergic airway inflammation inhibits pulmonary antibacterial host defense. *J. Immunol.* *177*, 1833–1837.
- Bergeron, C., Al-Ramli, W., and Hamid, Q. (2009). Remodeling in asthma. *Proc. Am. Thorac. Soc.* *6*, 301–305.
- Bonser, L.R., and Erle, D.J. (2017). Airway mucus and asthma: the role of MUC5AC and MUC5B. *J. Clin. Med.* *6*, 112.
- Borrell, L.N., Nguyen, E.A., Roth, L.A., Oh, S.S., Tcheurekdjian, H., Sen, S., Davis, A., Farber, H.J., Avila, P.C., Brigino-Buenaventura, E., et al. (2013). Childhood obesity and asthma control in the GALA II and SAGE II studies. *Am. J. Respir. Crit. Care Med.* *187*, 697–702.
- Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Hedgecock, S., Blogg, M., and Cioppa, G.D. (2005). The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. *Allergy* *60*, 302–308.
- Castro, M., Zangrilli, J., Wechsler, M.E., Bateman, E.D., Brusselle, G.G., Bardin, P., Murphy, K., Maspero, J.F., O'Brien, C., and Korn, S. (2015). Reslizumab for inadequately controlled asthma with elevated blood eosinophil

counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir. Med.* **3**, 355–366.

Chen, G., Korfhagen, T.R., Xu, Y., Kitzmiller, J., Wert, S.E., Maeda, Y., Gregorieff, A., Clevers, H., and Whitsett, J.A. (2009). SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production. *J. Clin. Invest.* **119**, 2914–2924.

Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., Clark, N.R., and Ma'ayan, A. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**, 128.

Chen, G., Korfhagen, T.R., Karp, C.L., Impey, S., Xu, Y., Randell, S.H., Kitzmiller, J., Maeda, Y., Haitchi, H.M., Sridharan, A., et al. (2014). Foxa3 induces goblet cell metaplasia and inhibits innate antiviral immunity. *Am. J. Respir. Crit. Care Med.* **189**, 301–313.

Chioccioli, M., Feriani, L., Kotar, J., Bratcher, P.E., and Cicuta, P. (2019a). Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells. *Nat. Commun.* **10**, 1763.

Chioccioli, M., Feriani, L., Nguyen, Q., Kotar, J., Dell, S.D., Mennella, V., Amirav, I., and Cicuta, P. (2019b). Quantitative high-speed video profiling discriminates between DNAH11 and HYDIN variants of primary ciliary dyskinesia. *Am. J. Respir. Crit. Care Med.* **199**, 1436–1438.

Christenson, S.A., Steiling, K., van den Berge, M., Hijazi, K., Hiemstra, P.S., Postma, D.S., Lenburg, M.E., Spira, A., and Woodruff, P.G. (2015). Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **191**, 758–766.

Contoli, M., Ito, K., Padovani, A., Poletti, D., Marku, B., Edwards, M.R., Stanciu, L.A., Gnesini, G., Pastore, A., Spanevello, A., et al. (2015). Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. *Allergy* **70**, 910–920.

de Jong, P.M., van Sterkenburg, M.A., Hesseling, S.C., Kempenaar, J.A., Mulder, A.A., Mommaas, A.M., Dijkman, J.H., and Ponc, M. (1994). Ciliogenesis in human bronchial epithelial cells cultured at the air-liquid interface. *Am. J. Respir. Cell Mol. Biol.* **10**, 271–277.

Evans, C.M., Williams, O.W., Tuvim, M.J., Nigam, R., Mixides, G.P., Blackburn, M.R., DeMayo, F.J., Burns, A.R., Smith, C., Reynolds, S.D., et al. (2004). Mucin is produced by clara cells in the proximal airways of antigen-challenged mice. *Am. J. Respir. Cell Mol. Biol.* **31**, 382–394.

Everman, J.E., Rios, C., and Seibold, M.A. (2018). Utilization of air-liquid interface cultures as an in vitro model to assess primary airway epithelial cell responses to the type 2 cytokine interleukin-13. *Methods Mol. Biol.* **1799**, 419–432.

Fahy, J.V. (2015). Type 2 inflammation in asthma—present in most, absent in many. *Nat. Rev. Immunol.* **15**, 57–65.

Feriani, L., Juenet, M., Fowler, C.J., Bruot, N., Chioccioli, M., Holland, S.M., Bryant, C.E., and Cicuta, P. (2017). Assessing the collective dynamics of motile cilia in cultures of human airway cells by multiscale DDM. *Biophys. J.* **113**, 109–119.

George, L., and Brightling, C.E. (2016). Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. *Ther. Adv. Chronic Dis.* **7**, 34–51.

Gerovac, B.J., and Fregien, N.L. (2016). IL-13 inhibits multicilin expression and ciliogenesis via Janus kinase/signal transducer and activator of transcription independently of notch cleavage. *Am. J. Respir. Cell Mol. Biol.* **54**, 554–561.

Gomperts, B.N., Kim, L.J., Flaherty, S.A., and Hackett, B.P. (2007). IL-13 regulates cilia loss and foxj1 expression in human airway epithelium. *Am. J. Respir. Cell Mol. Biol.* **37**, 339–346.

Hackett, N.R., Shaykhiev, R., Walters, M.S., Wang, R., Zwick, R.K., Ferris, B., Witover, B., Salit, J., and Crystal, R.G. (2011). The human airway epithelial basal cell transcriptome. *PLoS ONE* **6**, e18378.

Ishikawa, H., and Marshall, W.F. (2011). Ciliogenesis: building the cell's antenna. *Nat. Rev. Mol. Cell Biol.* **12**, 222–234.

Jiang, H., Lei, R., Ding, S.W., and Zhu, S. (2014). Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. *BMC Bioinformatics* **15**, 182.

Juhn, Y.J. (2014). Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease? *J. Allergy Clin. Immunol.* **134**, 247–257, quiz 258–259.

Kesimer, M., Kirkham, S., Pickles, R.J., Henderson, A.G., Alexis, N.E., Demaria, G., Knight, D., Thornton, D.J., and Sheehan, J.K. (2009). Tracheobronchial air-liquid interface cell culture: a model for innate mucosal defense of the upper airways? *Am. J. Physiol. Lung Cell. Mol. Physiol.* **296**, L92–L100.

Korfhagen, T.R., Kitzmiller, J., Chen, G., Sridharan, A., Haitchi, H.M., Hegde, R.S., Divanovic, S., Karp, C.L., and Whitsett, J.A. (2012). SAM-pointed domain ETS factor mediates epithelial cell-intrinsic innate immune signaling during airway mucous metaplasia. *Proc. Natl. Acad. Sci. U S A* **109**, 16630–16635.

Kumar, R., Nguyen, E.A., Roth, L.A., Oh, S.S., Gignoux, C.R., Huntsman, S., Eng, C., Moreno-Estrada, A., Sandoval, K., Peñaloza-Espinosa, R.I., et al. (2013). Factors associated with degree of atopy in Latino children in a nationwide pediatric sample: the Genes-environments and Admixture in Latino Asthmatics (GALA II) study. *J. Allergy Clin. Immunol.* **132**, 896–905.e1.

Kuperman, D.A., Huang, X., Koth, L.L., Chang, G.H., Dolganov, G.M., Zhu, Z., Elias, J.A., Sheppard, D., and Erle, D.J. (2002). Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. *Nat. Med.* **8**, 885–889.

Kuznetsova, A., Brockhoff, P.B., and Christensen, R.H.B. (2017). ImerTest package: tests in linear mixed effects models. *J. Stat. Softw.* **82**, 1–26.

Lachowicz-Scroggins, M.E., Yuan, S., Kerr, S.C., Dunican, E.M., Yu, M., Carrington, S.D., and Fahy, J.V. (2016). Abnormalities in MUC5AC and MUC5B protein in airway mucus in asthma. *Am. J. Respir. Crit. Care Med.* **194**, 1296–1299.

Laoukili, J., Perret, E., Willems, T., Minty, A., Parthoens, E., Houcine, O., Coste, A., Jorissen, M., Marano, F., Caput, D., and Tournier, F. (2001). IL-13 alters mucociliary differentiation and ciliary beating of human respiratory epithelial cells. *J. Clin. Invest.* **108**, 1817–1824.

Liu, Y., Zhang, S., Li, D.W., and Jiang, S.J. (2013). Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. *PLoS ONE* **8**, e59872.

Livraghi-Butrico, A., Grubb, B.R., Wilkinson, K.J., Volmer, A.S., Burns, K.A., Evans, C.M., O'Neal, W.K., and Boucher, R.C. (2017). Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. *Mucosal Immunol.* **10**, 395–407.

Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550.

Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet. J.* **17**, 10.

Montoro, D.T., Haber, A.L., Biton, M., Vinarsky, V., Lin, B., Birket, S.E., Yuan, F., Chen, S., Leung, H.M., Villoria, J., et al. (2018). A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. *Nature* **560**, 319–324.

Nair, P., Wenzel, S., Rabe, K.F., Bourdin, A., Lugogo, N.L., Kuna, P., Barker, P., Sproule, S., Ponnarambil, S., and Goldman, M.; ZONDA Trial Investigators (2017). Oral glucocorticoid-sparing effect of Benralizumab in severe asthma. *N. Engl. J. Med.* **376**, 2448–2458.

Neophytou, A.M., White, M.J., Oh, S.S., Thakur, N., Galanter, J.M., Nishimura, K.K., Pino-Yanes, M., Torgerson, D.G., Gignoux, C.R., Eng, C., et al. (2016). Air pollution and lung function in minority youth with asthma in the GALA II (Genes-Environments and Admixture in Latino Americans) and SAGE II (Study of African Americans, Asthma, Genes, and Environments) studies. *Am. J. Respir. Crit. Care Med.* **193**, 1271–1280.

Nicodemus-Johnson, J., Naughton, K.A., Sudi, J., Hogarth, K., Naurekas, E.T., Nicolae, D.L., Sperling, A.I., Solway, J., White, S.R., and Ober, C. (2016). Genome-wide methylation study identifies an IL-13-induced epigenetic signature in asthmatic airways. *Am. J. Respir. Crit. Care Med.* **193**, 376–385.

Nishimura, K.K., Galanter, J.M., Roth, L.A., Oh, S.S., Thakur, N., Nguyen, E.A., Thyne, S., Farber, H.J., Serebrisky, D., Kumar, R., et al. (2013). Early-life air

- pollution and asthma risk in minority children. The GALA II and SAGE II studies. *Am. J. Respir. Crit. Care Med.* **188**, 309–318.
- Noonan, M., Korenblat, P., Mosesova, S., Scheerens, H., Arron, J.R., Zheng, Y., Putnam, W.S., Parsey, M.V., Bohlen, S.P., and Matthews, J.G. (2013). Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. *J. Allergy Clin. Immunol.* **132**, 567–574.e12.
- Ordovas-Montanes, J., Dwyer, D.F., Nyquist, S.K., Buchheit, K.M., Vukovic, M., Deb, C., Wadsworth, M.H., 2nd, Hughes, T.K., Kazer, S.W., Yoshimoto, E., et al. (2018). Allergic inflammatory memory in human respiratory epithelial progenitor cells. *Nature* **560**, 649–654.
- Park, K.S., Korfhagen, T.R., Bruno, M.D., Kitzmiller, J.A., Wan, H., Wert, S.E., Khurana Hershey, G.K., Chen, G., and Whitsett, J.A. (2007). SPDEF regulates goblet cell hyperplasia in the airway epithelium. *J. Clin. Invest.* **117**, 978–988.
- Pezzulo, A.A., Starner, T.D., Scheetz, T.E., Traver, G.L., Tilley, A.E., Harvey, B.G., Crystal, R.G., McCray, P.B., Jr., and Zabner, J. (2011). The air-liquid interface and use of primary cell cultures are important to recapitulate the transcriptional profile of in vivo airway epithelia. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **300**, L25–L31.
- Plasschaert, L.W., Žilionis, R., Choo-Wing, R., Savova, V., Knehr, J., Roma, G., Klein, A.M., and Jaffe, A.B. (2018). A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. *Nature* **560**, 377–381.
- Poole, A., Urbanek, C., Eng, C., Schageman, J., Jacobson, S., O'Connor, B.P., Galanter, J.M., Gignoux, C.R., Roth, L.A., Kumar, R., et al. (2014). Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease. *J. Allergy Clin. Immunol.* **133**, 670–8.e12.
- Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140.
- Roy, M.G., Livraghi-Butrico, A., Fletcher, A.A., McElwee, M.M., Evans, S.E., Boerner, R.M., Alexander, S.N., Bellinghausen, L.K., Song, A.S., Petrova, Y.M., et al. (2014). Muc5b is required for airway defence. *Nature* **505**, 412–416.
- Ruiz García, S., Deprez, M., Lebrigand, K., Cavard, A., Paquet, A., Arguel, M.J., Magnone, V., Truchi, M., Caballero, I., Leroy, S., et al. (2019). Novel dynamics of human mucociliary differentiation revealed by single-cell RNA sequencing of nasal epithelial cultures. *Development* **146**, dev177428.
- Russell, R.J., Chachi, L., FitzGerald, J.M., Backer, V., Olivenstein, R., Titlestad, I.L., Ulrik, C.S., Harrison, T., Singh, D., Chaudhuri, R., et al.; MESOS study investigators (2018). Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. *Lancet Respir. Med.* **6**, 499–510.
- Satija, R., Farrell, J.A., Gennert, D., Schier, A.F., and Regev, A. (2015). Spatial reconstruction of single-cell gene expression data. *Nat. Biotechnol.* **33**, 495–502.
- Thielicke, W., and Stamhuis, E.J. (2014). PIVlab—towards user-friendly, affordable and accurate digital particle image velocimetry in MATLAB. *J. Open Res. Softw.* **2**, e30.
- Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N.J., Livak, K.J., Mikkelsen, T.S., and Rinn, J.L. (2014). The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat. Biotechnol.* **32**, 381–386.
- Turner, J., Roger, J., Fitau, J., Combe, D., Giddings, J., Heeke, G.V., and Jones, C.E. (2011). Goblet cells are derived from a FOXJ1-expressing progenitor in a human airway epithelium. *Am. J. Respir. Cell Mol. Biol.* **44**, 276–284.
- Tyner, J.W., Kim, E.Y., Ide, K., Pelletier, M.R., Roswit, W.T., Morton, J.D., Battaile, J.T., Patel, A.C., Patterson, G.A., Castro, M., et al. (2006). Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. *J. Clin. Invest.* **116**, 309–321.
- Wark, P.A.B., Johnston, S.L., Bucchieri, F., Powell, R., Puddicombe, S., Laza-Stanca, V., Holgate, S.T., and Davies, D.E. (2005). Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J. Exp. Med.* **201**, 937–947.
- Woehlk, C., von Bülow, A., Kriegbaum, M., Backer, V., and Porsbjerg, C. (2018). Allergic asthma is associated with increased risk of infections requiring antibiotics. *Ann. Allergy Asthma Immunol.* **120**, 169–176.e1.
- Woodruff, P.G., Modrek, B., Choy, D.F., Jia, G., Abbas, A.R., Ellwanger, A., Koth, L.L., Arron, J.R., and Fahy, J.V. (2009). T-helper type 2-driven inflammation defines major subphenotypes of asthma. *Am. J. Respir. Crit. Care Med.* **180**, 388–395.
- Wu, T.D., and Nacu, S. (2010). Fast and SNP-tolerant detection of complex variants and splicing in short reads. *Bioinformatics* **26**, 873–881.
- Wu, Q., Jiang, D., Smith, S., Thaikootathil, J., Martin, R.J., Bowler, R.P., and Chu, H.W. (2012). IL-13 dampens human airway epithelial innate immunity through induction of IL-1 receptor-associated kinase M. *J. Allergy Clin. Immunol.* **129**, 825–833.e2.
- Zhang, B., and Horvath, S. (2005). A General Framework for Weighted Gene Co-expression Network Analysis, *Volume 4* (The Berkeley Electronic Press).
- Zhao, H., Albino, A.P., Jorgensen, E., Traganos, F., and Darzynkiewicz, Z. (2009). DNA damage response induced by tobacco smoke in normal human bronchial epithelial and A549 pulmonary adenocarcinoma cells assessed by laser scanning cytometry. *Cytometry A* **75**, 840–847.
- Zhao, S., Guo, Y., Sheng, Q., and Shyr, Y. (2014). Advanced heat map and clustering analysis using heatmap3. *BioMed Res. Int.* **2014**, 986048.
- Zhen, G., Park, S.W., Nguyenvu, L.T., Rodriguez, M.W., Barbeau, R., Paquet, A.C., and Erle, D.J. (2007). IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production. *Am. J. Respir. Cell Mol. Biol.* **36**, 244–253.
- Zhu, Z., Homer, R.J., Wang, Z., Chen, Q., Geba, G.P., Wang, J., Zhang, Y., and Elias, J.A. (1999). Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. *J. Clin. Invest.* **103**, 779–788.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
mouse anti-MUC5AC	Invitrogen	MA1-38223; RRID:AB_2266697
rabbit anti-SCGB1A1	BioVendor	RD181022220-01; RRID:AB_344578
mouse anti-E-cadherin	ECM Biosciences	CM1681; RRID:AB_2076812
donkey anti-rabbit IgG (H+L)	Invitrogen	A-21207, A-31573; RRID:AB_141637, RRID:AB_2536183
donkey anti-mouse IgG (H+L)	Invitrogen	A-21203, A-31571; RRID:AB_141633, RRID:AB_162542
Biological Samples		
Human tracheal epithelial cells (HTECs)	Seibold Laboratory at National Jewish Health	N/A
Human bronchial epithelial cells (HBECs)	National Jewish Live Cell Core	N/A
Human nasal epithelial cells from Genes-environments & Admixture in Latino Americans II (GALA II)	Seibold Laboratory at National Jewish Health	N/A
Chemicals, Peptides, and Recombinant Proteins		
DMEM-F (high glucose 4.5g/L)	Fisher Scientific	10-017-CV
Ham's F-12	ThermoFisher Scientific	11765-054
FBS (heat-inactivated)	LifeTechnologies	10082-147
L-glutamine	Fisher Scientific	MT25005CI
Penicillin/Streptomycin (P/S)	Fisher Scientific	MT30002CI
Hydrocortisone	Sigma	H-0888
EGF (for F-media)	Fisher Scientific	17005042
Cholera Toxin	Sigma	C-8052
Insulin	Sigma	I9278
Adenine	Sigma	A8626
Rock1 Inhibitor (RI) (Y-27632 dihydrochloride)	APExBio	A3008
Amphotericin B	Sigma	A2942
Fluconazole	Fagron, Inc.	803890
Gentamicin Reagent	ThermoFisher Scientific	15710064
PureCol Type I Bovine Collagen	Advanced Biomatrix	5005-100ml
BEBM Basal Medium	Lonza	CC-3171
DMEM-C (low glucose 1g/L)	ThermoFisher Scientific	11885084
Bovine Serum Albumin (BSA)	Sigma	A2153
Ethanolamine	Sigma	E0135
human EGF (hEGF) (for ALI Expansion Medium)	EMD Millipore	01-107
MgSO4	Sigma	M7506
MgCl2	Sigma	M8266
CaCl2	Sigma	C4901
Retinoic Acid	Sigma	R2625
BEGM Brochial Epithelial SingleQuots Kit	Lonza	CC-4175
PneumaCult ALI Medium Kit	StemCell Technologies	#05001
Heparin Solution (2mg/ml)	StemCell Technologies	#07980
Hydrocortisone Stock Solution	StemCell Technologies	#07925
Interleukin 13 (IL-13)	R&D Systems	213-ILB-005
1x PBS (without Ca/Mg)	Fisher Scientific	21-040-CV

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Trypsin	Fisher Scientific	25-053-CI
1X HBSS	Fisher Scientific	21-021-CV
DNase	Sigma	DN25
Accutase	Fisher Scientific	NC9839010
EDTA (0.5M)	Fisher Scientific	BP2482-500
EGTA (0.5M)	Fisher Scientific	50-255-957
Paraformaldehyde (16%), MeOH Free	Fisher Scientific	AA433689M
HistoChoice Clearing Agent	Sigma	H2779
Molecular Grade Ethanol (100%)	Fisher Scientific	BP28184
Antigen Unmasking Solution, Citrate based	Vector Labs	H-3300
Triton X-100	Sigma	T8787
Tris-Buffered Saline (TBS - 20x)	Fisher Scientific	AAJ60877K3
DAPI (4',6-diamidino-2-phenylindole)	Sigma	D9542
VectaShield HardSet Antifade Mounting Media	Vector Laboratories	H-1400
10% Neutral Buffered Formalin	Sigma	HT501128
LC/MS grade Methanol	Fisher Scientific	A456-500
Trypsin (proteomics grade)	Promega	V5280
Trifluoroethanol	Fisher Scientific	AC13975-1000
Ammonium Bicarbonate	Fisher Scientific	BP2413500
Dithiothreitol (DTT)	Biorad	1610611
Iodoacetamide	Biorad	1632109
Formic Acid	Fisher Scientific	PI28905
Acetonitrile	Fisher Scientific	A955-4
Deposited Data		
Single cell RNA-seq data (fastq and processed data files)	GEO	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145013
Bulk RNA-seq data from GALA II (fastq and processed data files)	GEO	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152004
Experimental Models: Cell Lines		
NIH 3T3 Fibroblasts (feeders)	ATCC	#CRL-1658
Software and Algorithms		
DataAnalysis 4.2	Bruker	https://www.bruker.com/
Mascot 2.4	Matrix Science	http://www.matrixscience.com/index.html
Percolator (algorithm)	Matrix Science	http://www.matrixscience.com/help/percolator_help.html
ProteinScape 3.0	Bruker	https://www.bruker.com/
Particle Tracker - ImageJ	ImageJ	https://imagej.nih.gov/ij/
iGenomes GTF (hg38)	UCSC	https://emea.support.illumina.com/sequencing/sequencing_software/igenome.html
PIVlab	Thielicke and Stamhuis, 2014	https://www.mathworks.com/matlabcentral/fileexchange/27659-pivlab-particle-image-velocimetry-piv-tool
Cutadapt version 2.4	Martin, 2011	https://cutadapt.readthedocs.io/en/stable/
Skewer version 0.2.2	Jiang et al., 2014	https://github.com/relipmoc/skewer
GSNAP version 2016_05_01	Wu and Nacu, 2010	http://research-pub.gene.com/gmap/
HTSeq-count version 0.8.0	Anders et al., 2015	https://htseq.readthedocs.io/en/release_0.11.1/count.html
DESeq2 version 1.16.1	Love et al., 2014	https://bioconductor.org/packages/release/bioc/html/DESeq2.html

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
edgeR version 3.24.0	Robinson et al., 2010	https://bioconductor.org/packages/release/bioc/html/edgeR.html
Seurat version 2.3.0	Satija et al., 2015	https://cran.r-project.org/web/packages/Seurat/index.html
heatmap3 version 1.1.1	Zhao et al., 2014	https://cran.r-project.org/web/packages/heatmap3/index.html
EnrichrAPI	Chen et al., 2013	https://github.com/russell-stewart/enrichrAPI
Monocle version 2.8	Trapnell et al., 2014	https://bioconductor.org/packages/release/bioc/html/monocle.html
WGCNA version 1.61	Zhang and Horvath, 2005	https://cran.r-project.org/web/packages/WGCNA/index.html
lmerTest version 3.0	Kuznetsova et al., 2017	https://cran.r-project.org/web/packages/lmerTest/index.html
Custom Code	This study	https://github.com/seiboldlab/SingleCell_IL13
Other		
Echo Revolve R4 Microscope	Discover Echo, Inc.	https://discover-echo.com/revolve
Beckman Coulter FXp Automation System	Beckman Coulter	https://www.beckmancoulter.com/
HiSeq 2500 System	Illumina	https://www.illumina.com/
Bruker Mass Spec	Bruker	https://www.bruker.com/
Eclipse Ti-E inverted microscope	Nikon	https://www.nikon.com/
CMOS camera	FLIR Integrated Imaging Solutions Inc.	GS3-U3-23S6M-C
6.5mm transwell inserts, 0.4um PET membrane	Corning	3470
SuperFrost Plus Sides	Fisher Scientific	12-550-15
Siliconized protein low-bind eppendorf tubes (2ml)	Fisher Scientific	02-681-332
ProntoSIL C18AQ Column (15cm x 100um)	nanoLCMS Solutions	31001
Capillary 3μ 200Å ProntoSIL C18AQ Trap	nanoLCMS Solutions	41002
SwissProt	UniProtKB/Swiss-Prot	https://www.expasy.org/proteomics/

RESOURCE AVAILABILITY

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Max A. Seibold, Ph.D. (seiboldm@njhealth.org).

Materials Availability

This study did not generate new unique reagents.

Data and Code Availability

Raw and processed RNA-seq data used in the study are available at the National Center for Biotechnology Information/Gene Expression Omnibus (GEO) under repository accession number GEO: GSE145013 [<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145013>] for the scRNA-seq data and under GEO: GSE152004 [<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152004>] for bulk RNA-seq data from GALA II. Proteomics and CBF data used to generate Figures 6 and S4 are available in Table S6. Code used to carry out data analysis is available on GitHub [https://github.com/seiboldlab/SingleCell_IL13].

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human tracheal samples

For single cell RNA sequencing, human tracheal epithelial cells (HTEC) were isolated from two de-identified donors (T71 and T72) whose lungs were not suitable for transplantation (see Table S2). HTEC samples were isolated from several additional donors for use in cell imaging (T73, T76, and T79 were used for imaging in Figures 3A, 5D, and S2B and T147 and T148 were used in Figure S2D).

All lung specimens were obtained from the International Institute for the Advancement of Medicine (Edison, NJ) and the Donor Alliance of Colorado. The National Jewish Health Institutional Review Board (IRB) approved the research under IRB protocols HS-3209 and HS-2240.

Human bronchial samples

Human Bronchial Epithelial Cells (HBEC) were acquired from the National Jewish Live Cell Core/Mucosal Immunity Program (Denver, CO) for use in proteomic and functional assays. The National Jewish Health Institutional Review Board (IRB) approved the research under IRB protocol HS-2240. Basal cells were obtained from 14 age- and sex-matched donors (4 control and 10 asthmatic) with no history of smoking (see [Table S3](#)).

GALA II nasal airway epithelial samples

Nasal AECs used in this study came from subjects recruited as part of the Genes-environments & Admixture in Latino Americans II (GALA II) childhood asthma cohort, which was approved by local institutional review boards (University of California, San Francisco, IRB number 10-00889, reference number 153543; National Jewish Health, IRB number HS-2627). All subjects and their parents provided written informed assent and consent, respectively ([Neophytou et al., 2016](#); [Nishimura et al., 2013](#)). Demographic and clinical variables for GALA II tissue donors used in this study are listed in [Table S4](#).

Whole transcriptome RNA-seq data were collected from 254 control subjects and 441 asthma subjects, where asthmatics were defined as those having received an asthma diagnosis by a physician and having exhibited two or more symptoms within the two years prior to enrollment. See [Borrell et al. \(2013\)](#) and [Kumar et al. \(2013\)](#) for more in depth descriptions of the study.

Air-liquid interface *in vitro* model

To model the transcriptional, proteomic, and functional responses to T2 inflammation in the human airway epithelium, we used cell cultures established and grown at air-liquid interface (ALI) ([Everman et al., 2018](#)). These ALI cultures were initially seeded with primary basal cells from tracheal or bronchial epithelial samples and then allowed to differentiate into functional, mucociliary airway epithelia consisting of a mix of basal, secretory, and ciliated cells that respond to environmental insults in ways expected to be similar to their responses *in vivo* ([de Jong et al., 1994](#); [Kesimer et al., 2009](#); [Pezzulo et al., 2011](#)). We stimulated T2 inflammation using interleukin-13 (IL-13), which is known to recapitulate many of the features of T2H asthma, both *in vivo* ([Chen et al., 2009](#); [Tyner et al., 2006](#); [Zhen et al., 2007](#)) and *in vitro* ([Gerovac and Fregien, 2016](#); [Nicodemus-Johnson et al., 2016](#); [Zhao et al., 2009](#)).

METHOD DETAILS

ALI culture differentiation and IL-13 stimulation - HTEC stimulation experiments for scRNA-seq

Primary basal HTECs from the two donors were isolated and expanded for 2 passages on NIH 3T3 fibroblast feeders using F-medium (67.5% DMEM-F, 25% Ham's F-12, 7.5% FBS, 1.5 mM L-glutamine, 25 ng/mL hydrocortisone, 12.5 ng/mL EGF, 8.6 ng/mL cholera toxin, 24 µg/mL Adenine, 0.1% insulin, 75 U/mL pen/strep) with ROCK1 Inhibitor (RI, 10 µM) and antibiotics (1.25 µg/mL amphotericin B, 2 µg/mL fluconazole, 50 µg/mL gentamicin). Passage 2 cell suspensions were harvested by trypsinization, treated with DNase (12.5 mg/ml) in HBSS for 5 min at 37°C, and seeded onto bovine collagen-coated 6.5 mm transwell inserts (2x10⁴ cells/insert for acute stimulation, 1x10⁴ cells/insert for chronic stimulation) in ALI expansion medium (50% BEBM, 50% DMEM-C, 0.5 mg/mL BSA, 80 µM ethanolamine, 10 ng/mL hEGF, 0.4 µM MgSO₄, 0.3 µM MgCl₂, 1 µM CaCl₂, 30 ng/mL retinoic acid, 0.8X insulin*, 0.5X transferrin*, 1X hydrocortisone*, 1X epinephrine*, 1X bovine pituitary extract*, 1X gentamicin/amphotericin* (*relative to BEGM Bullet Kit aliquot) with RI. RI was removed after 24 hours and confluent monolayers were airlifted 6 (acute stimulation) or 7 (chronic stimulation) days post seed and differentiated using complete PneumaCult ALI media made as per manufacturer's instructions. Starting at day 21 (acute stimulation) or day 11 (chronic stimulation) post-airlift, paired cultures for each donor were stimulated with IL-13 or BSA for 48 hours (acute stimulation) or 11 days (chronic stimulation), after which cells were harvested on day 23 (acute stimulation) or day 22 (chronic stimulation).

ALI culture differentiation and IL-13 stimulation - HBEC stimulation experiments for proteomic and functional assays

Primary basal HBECs were isolated and expanded for 2 passages on NIH 3T3 fibroblast feeders using F-medium with ROCK1 Inhibitor (RI, 10 µM). Cell suspensions were harvested by trypsinization, treated with DNase (12.5 mg/ml) in HBSS for 5 minutes at 37°C, and seeded onto 6.5 mm, 0.4 µm pore transmembrane inserts pre-coated with PureCol bovine collagen (2x10⁴ cells/insert) in ALI expansion medium with RI, and RI was removed after 24 hours. Upon confluence, air-liquid interface was established and cultures were allowed to differentiate using PneumaCult ALI (PC-ALI) differentiation media. At day 11 post-airlift, paired cultures for each donor were stimulated with IL-13 (10 ng/ml) or BSA daily for 10 days until day 21. For functional mucociliary assays, cultures were used for cilia beat frequency analysis as described below. For apical proteomic analysis, following 10 day IL-13 stimulation, each insert was washed three times with warm PBS using a new plate well to remove any contaminating media proteins carried over from the cultures and plasticware. Inserts were then stimulated either with IL-13 or BSA alone in base PneumaCult ALI media

in the absence of suggested additives and media components. After 24 hours, the apical chambers of each well were washed two times with warm PBS, collected, and pooled. Soluble and insoluble fractions were isolated and processed separately, as detailed below.

Harvesting of cells for scRNA-seq

Replicate mature stimulated ALI cultures were washed with warm PBS/DTT (10 mM) for 5 minutes at 37°C, followed by a warm PBS wash of both chambers. Cultures were then harvested from the filter to single cell suspensions using apical dissociation solution (Accutase with 5 mM EDTA and 5 mM EGTA) for 30 minutes at 37°C with occasional manual agitation (Everman et al., 2018). Single cell suspensions were diluted, centrifuged, and washed once with PBS/DTT and twice with PBS before sorting for live singlets. Cells from both tracheal donors and treatments were dispensed into each of two 5,184-nanowell version 1 microchips (91497 and 94576) (for the acute IL-13 experiment) or into a single version 2 microchip (97570) (for the chronic IL-13 experiment) using the ICELL8 platform (Takara Bio USA, Inc.), after which non-doublet cells were selected for library preparation and sequencing.

Single cell RNA isolation and sequencing

Library preparation was carried out using ICELL8 single-cell poly-(A)+ transcriptome amplification hands-on workflow (with Triton X-100 for cell lysis), protocol D07-000040-003 rev4. For the acute IL-13 experiment, libraries were generated for a total of 2,385 selected cells from the two tracheal donors (plus positive and negative controls), after which they were sequenced as 100 base pair single-end reads on an Illumina HiSeq 2500 (Illumina, Inc., San Diego, CA), with cells from each of the two microchips sequenced across three flow cell lanes. For the chronic IL-13 experiment, the same approach was used, except that 802 single cells were selected for sequencing and then sequenced across three flow cell lanes. See Table S5 for a summary of sequencing statistics for cells stratified by dataset, treatment, and donor.

Immunofluorescence microscopy

Intact differentiated ALI culture inserts were fixed for 15 minutes at room temperature in 3.2% paraformaldehyde. For histological sections, fixed ALIs were embedded in paraffin and sectioned onto microscope slides. Sections were stripped of paraffin using HistChoice Clearing Agent and rehydrated using a decreasing gradient of alcohol washes (100%, 90%, 70%, 50%, 30%, 0%), followed by antigen retrieval conducted using Citric Acid-based Antigen Unmasking Solution (pH 6.0). Histologic sections were blocked and permeabilized (3% BSA, 0.4% Triton X-100, 1X TBS) for 30 minutes at room temperature, and immunolabeled with primary antibodies (3% BSA, 0.1% Triton X-100, 1X TBS) overnight at 4°C with dilutions as follows: SCGB1A1 (1:1500), MUC5AC (1:500). Whole-mount samples were blocked and permeabilized for 30 minutes using 3% BSA/0.1% Triton X-100 in tris-buffered saline (TBS) followed by primary labeling using 3% BSA/0.1% Triton X-100 in TBS for 1 hour with antibodies against MUC5AC (1:500), SCGB1A1 (1:500). All samples were washed twice using TBS/0.1% Triton X-100 (TBST) and secondary labeling was conducted using DAPI (1:1000), and either donkey anti-rabbit IgG or anti-mouse IgG (1:500) conjugated to AlexaFluor488 or AlexaFluor 594 dyes for 30 minutes. Slides were washed twice and mounted with Vectashield HardSet Antifade Mounting Media. Images were acquired using an Echo Revolve R4 microscope.

Fluorescence *in situ* hybridization (RNAScope)

ALI cultures rinsed with PBS were fixed in 10% neutral buffered formalin for 24+/- 8 hours at room temperature, washed with 1X PBS, paraffin-embedded, and sectioned onto SuperFrost Plus slides. Sections were dried overnight, baked for 1 hour at 60°C, and stored for 1 week before proceeding with the RNAScope Multiplex Fluorescent v2 assay according to the manufacturer's instructions with the following modifications: target retrieval was performed for 15 minutes in a boiling beaker, Protease III was used for 30 minutes pre-treatment at 40°C, and hybridized slides were left overnight in 5X SSC before proceeding with the amplification steps. Opal fluoros were applied at 1:1500 dilution and before mounting. Immunofluorescence labeling (E-cadherin: 1:2500; FOXJ1: 1:500) was performed as outlined above, except with 1 hour of primary application at room temperature. Slides were imaged on an Echo Revolve R4 microscope (Discover Echo, Inc) or a Zeiss LSM700 confocal microscope.

Proteomic sample preparation

Apical washes from paired BSA and IL-13-treated ALI cultures were collected in Fisher 2 mL low binding microfuge tubes and then samples were centrifuged at 225 x g at 4°C to remove intact cells from the washes. Supernatants were collected from each sample and the visible insoluble (i.e., mucus) fraction was removed from each wash, dried in a SpeedVac at 45°C, and stored at -80°C. The remaining soluble apical fraction was mixed with 3x volume of ice cold LC/MS grade methanol followed by incubation at -80°C for 1 hour. Proteins were then pelleted by centrifugation at 18,000 x g and the supernatant was removed. Protein pellets were dried in a SpeedVac at 45°C and frozen at -80°C. For trypsin digestion, protein pellet pairs were denatured and reduced using 50% trifluoroethanol in 50 mM ammonium bicarbonate with 0.1 mM DTT at 65°C for 45 minutes. Proteins were then alkylated for 1 hour in the dark using 0.32 mM iodoacetamide, and excess IAA was then reduced using 0.08 mM DTT for 1 hour in the dark. Samples were diluted with 400 µL of 25 mM ammonium bicarbonate buffer and digested with 0.3 µg of trypsin for 5 hours at 37°C. Digests were then stopped using 2 µL of formic acid and duplicate samples were combined and dried at 45°C in a SpeedVac concentrator. Dried samples were stored at -70°C until mass spectrometry analysis.

Mass spectrometry

Mass spectrometry analysis was carried out for the soluble fraction from all 14 donors and for the mucus fraction from a subset of six donors. Samples were first resuspended with 10 μ L of 3% Acetonitrile + 0.1% formic acid and the total sample was analyzed using a nanoAdvanced UPLC (Bruker) with a 15 cm \times 100 μ m ProntoSil C18AQ column and 2 cm trap column (nanoLCMS Solutions). Mobile phase was H₂O + 0.1% FA (A) and acetonitrile + 0.1% FA (B), peptides were separated using a gradient of 2%–40% B over 30 minutes at a flow rate of 800 nL/minute and with the column temperature kept constant at 40°C. The column was connected through a Captive Spray nano source to an Impact Q-tof (Bruker). Data were collected over a mass range of 150–2200 m/z using a 1 Hz MS scan and a total duty cycle time of 2 s, a setting that allows the Impact to adjust the acquisition time for each fragment scan based on precursor intensity while still collecting data on as many precursors as possible without exceeding the 2 s duty cycle. Data were processed using DataAnalysis 4.2 (Bruker), compounds were searched against the SwissProt database using Mascot 2.4 (Matrix Science) with the percolator algorithm, and protein and peptide results were assessed and filtered with ProteinScape 3.0 (Bruker).

Top-down imaging and measurement of ciliary beat frequency

Using six paired HBECC ALI cultures chronically stimulated with IL-13 or BSA as described above, we measured ciliary beat frequency (CBF) based on top-down imaging in order to assess functional response to IL-13 in these epithelia. ALI cultures were first washed once in 37°C PBS for 10 minutes, after which the wash was removed and cultures were imaged by placing the plastic insert in a glass-bottom Petri dish with 1 mL of PC-ALI medium.

Digital high-speed videos were recorded on 5 different fields of view across the sample, (FOV = 1920 \times 1024 px, 1 px = 0.146 μ m), under bright-field illumination and at a sampling frequency of 150 fps using a Nikon Eclipse Ti-E inverted microscope (Nikon Instruments, Japan) with a 40x objective (Plan Apo λ 40 \times , N.A. 0.95, Nikon) fitted with a Grasshopper[®]3 GS3-U3-23S6M-C CMOS camera (FLIR Integrated Imaging Solutions GmbH, Germany). Samples of epithelial cells were imaged in a custom-made chamber, where temperature, CO₂ and humidity were continuously monitored and maintained at values of 37°C, 5%, and 90%, respectively, by using custom software running on a Linux machine. Imaging was repeated as described above for these same inserts after they were subjected to a PBS + 10 mM DTT wash (10 minutes at 37°C) aimed at hydrating and denaturing the mucus layer. CBF was quantified using Differential Dynamic Microscopy, as previously described (Chioccioli et al., 2019a; Feriani et al., 2017). Briefly, each field of view was first divided into tiles of 64 \times 64 px (\sim 9 μ m per side). The distribution of CBF in the field of view was then measured by running DDM on the tiles that showed motion and fitting its output with an empirical oscillating function (the Image Structure Function). The CBF distributions for each treatment were then built by pooling the values of CBF (in units of Hz) measured on the “active” tiles of all the fields of view imaged across the six sample. Total data points per treatment were as follows: control, unwashed = 11,782; IL-13, unwashed = 7,896; control, washed = 10,511; and IL-13 washed = 7,444.

Profile imaging of ciliary beating pattern

In order to capture a detailed ciliary beating pattern of the single cilium under IL-13 and control conditions, we carried out a similar experiment as described above using two paired HTEC donor ALI cultures chronically stimulated with IL-13 or BSA and then processed as previously described (Chioccioli et al., 2019b). Briefly, to perform high speed video microscopy on the cilia, the bottom membrane supporting the epithelium was excised from the plastic ALI insert. The membrane was then folded in half and placed between two coverslips, together with a few μ L of medium. The profile videos were then obtained by imaging the edge of the folded membrane. High speed videos were acquired at room temperature on an Eclipse Ti-E inverted microscope (Nikon, Japan) using a 60X water immersion objective (NA = 1.2, Nikon, Japan) and an additional 1.5X magnification in the optical path, and a CMOS camera (GS3-U3-23S6M-C, FLIR Integrated Imaging Solutions GmbH, Germany). The image acquisition was run by a custom software running on a Linux machine. About 10 videos were acquired per insert, at four different locations along the membrane’s edge. Videos were at least 10 s long, recorded with a framerate in excess of 200 fps (1px = 0.065 μ m).

To estimate CBF, videos were first analyzed using Particle Image Velocimetry implemented in PIVlab (Thielicke and Stamhuis, 2014), which yields a velocity field for each couple of subsequent frames. Using a custom MATLAB script, we then assessed at how this velocity field behaves as a function of the height from the cell surface (i.e., along the cilium). Specifically, we manually identified the surface of the ciliated cells, after which the script automatically found four measuring lines at distance 2.5 μ m, 3.5 μ m, 4.5 μ m and 5.5 μ m from the cell surface. The CBF was then obtained at each of the measuring lines by taking the Fourier transform of the lag time dependence of the autocorrelation of the kymograph of the component of the velocity parallel to the cell surface. Specifically, we first took the velocity measured at each frame by PIV along each measuring line and, at each point along it, we defined a frame of reference with two axes respectively parallel and perpendicular to the measuring line (which is in turn parallel to the cell surface). By projecting the velocity on the parallel axis, we obtained the component of the velocity that is parallel to the cell surface. By doing so we measured the velocity parallel to the cell surface at each point along the measuring line. We then build a kymograph of this quantity by repeating the procedure above on each of the frames analyzed by PIV. We then took the autocorrelation of the kymograph over time and space, and Fourier transform its behavior with the time lag. The frequency that corresponds to the peak in the Fourier spectrum is the average CBF along the measuring line.

Mucociliary movement analysis using particle tracking

Using the chronic stimulation model, ALI cultures were treated with IL-13 or BSA prior to particle tracking of cultures ($n = 6$). Inserts were placed onto a plastic Petri dish, and Cy5-labeled 5 μm beads were added to the apical chamber of each culture. For each sample, 10sec videos were captured on 4x magnification over 4 fields of view per culture. Videos were processed and particle tracking analysis was conducted using the Particle Tracker plug-in by ImageJ.

RNA extraction, library preparation, and sequencing for GALA II nasal epithelial brushings

Primary nasal AEC brushes obtained from GALA II cohort subjects were placed into RLT Plus lysis buffer for RNA and DNA extraction using the AllPrep DNA/RNA MiniPrep Kit (QIAGEN). RNA normalization, library construction using KAPA Stranded mRNA-Seq Kit with KAPA mRNA Capture Beads (KAPA Biosystems), and library pooling for a total of 695 subjects were all performed on the Beckman Coulter FX^P automation system. Briefly, RNA samples were randomized over the normalization plate in alternating control and asthmatic conditions at 250 ng per well. Illumina Dual-Index adapters (Integrated DNA Technologies) were used to barcode libraries using 12 cycles of amplification. Samples were pooled using equal concentrations of six libraries/pool and pair-end sequenced with Illumina HiSeq 2500 System sequencing.

QUANTIFICATION AND STATISTICAL ANALYSIS

Pre-processing of scRNA-seq data

We trimmed and culled raw demultiplexed cDNA reads in FASTQ files using Cutadapt (Martin, 2011), trimming poly A tails and 5' and 3' ends with $q < 20$ and removing any reads shorter than 25 base pairs. We then aligned trimmed reads to the hg38 human genome with GSNAP (Wu and Nacu, 2010), setting “max-mismatches=0.05” and accounting for both known Ensembl splice sites and SNPs. We quantified gene expression using HTSeq (Anders et al., 2015) with “stranded=yes,” “mode=intersection-nonempty,” and “t=gene” and then summed the number of unique molecular identifiers (UMIs) for each gene across runs for each cell to obtain a UMI count matrix that we used for all downstream analysis.

Although samples comprising multiple cells were removed during the cell selection stage, to safeguard against undetected doublets, we removed 34 outlier cells expressing $> 46,000$ UMIs (chip 91497 cells) or $> 28,500$ UMIs (chip 94576 cells) from the acute stimulation dataset and 10 outlier cells expressing $> 60,000$ UMIs from the chronic stimulation dataset. For the acute dataset, we also removed 11 cells for which the percentage of reads that mapped to genes was $< 50\%$. Prior to downstream analysis, we removed select mitochondrial and ribosomal genes (those beginning with *MTAT*, *MT-*, *MTCO*, *MTCY*, *MTERF*, *MTND*, *MTRF*, *MTRN*, *MRPL*, *MRPS*, *RPL*, *RPS*) and very lowly expressed genes (those genes not expressed in at least 0.5% of cells). Finally, we removed 446 cells expressing fewer than 2,500 UMIs from the acute dataset and three cells expressing fewer than 2,000 UMIs from the chronic dataset. The final QCed acute dataset contained 1,894 cells with a mean of 8,736 UMIs and 3,159 genes per cell and the final QCed chronic dataset contained 789 cells with a mean of 12,970 UMIs and 4,580 genes per cell.

Pre-processing of bulk RNA-seq data

Sequencing reads were trimmed with Skewer (Jiang et al., 2014) (–end-quality 15,–mean-quality 25,–min 30) and then aligned to human reference genome GRCh38 with GSNAP using splice site and SNP databases from iGenomes. Transcript quantification of these aligned reads on iGenomes GTF file were conducted with HTSeq (“stranded=no,” “mode=intersection-nonempty,” and “t=exon”).

Clustering and visualization of scRNA-seq data

For the acute simulation dataset, we accounted for differences in coverage across cells by dividing each cell's UMI count by the sum of all the cell's UMIs, multiplying by 10,000, and then taking the natural log. For input into dimensionality reduction and clustering analyses and for plotting relative expression in heatmaps and dot plots, we also fitted normalized expression of each gene to a set of predictors that included the sum of the UMI counts per cell and the identity of the originating donor and chip, and then mean centered (subtracted from each gene count the average expression of that gene) and scaled (divided each centered gene count by that gene's standard deviation) the residuals. We then used the top eight PC dimensions based on the top 8,070 most informative genes to visualize and cluster cells, where “informativeness” was defined by gene dispersion (i.e., the log of the ratio of expression variance to its mean) across cells, calculated after accounting for its relationship with mean expression. We visualized these top components of variation in two dimensions using the Barnes-Hut implementation of t-distributed neighborhood embedding (tSNE; perplexity = 45). We also carried out unsupervised clustering by first constructing a shared nearest neighbor (SNN) graph based on k-nearest neighbors ($k = 30$) calculated from PC dimensions and then determined the number and composition of clusters using a modularity function optimizer based on the Louvain algorithm (resolution = 1.1). We used the Seurat R package (Satija et al., 2015) to carry out all data normalization and scaling as well as downstream dimensionality reduction, clustering, tSNE plot overlaying, and differential expression.

Due to batch-based differences in expression between the two donors in the chronic stimulation dataset, we reduced the dimensionality of variation in that dataset using canonical correlation analysis (CCA), which identifies the strongest components of gene correlation structure that are shared across datasets (Seurat's RunMultiCCA function). After normalizing and scaling datasets for the two donors separately, we carried out CCA based on the 3,350 genes contained within the union of the top 2,000 most informative

genes from each donor. Correlated expression across donors based on the top three CCA dimensions was then projected into a common subspace using Seurat's AlignSubspace function, allowing us to identify and visualize universal populations of cells, rather than those driven by donor-specific variation. We removed 33 cells that were not well explained by these shared components (i.e., any gene for which variance explained by CCA was < 2-fold that explained by PCA). We then visualized these subspace-aligned CCA dimensions in two tSNE dimensions (perplexity = 30) and performed SNN clustering. Initial SNN clustering yielded six clusters (resolution = 0.6), four of which corresponded to secretory cell populations and two of which corresponded to ciliated cell populations (one ciliated cluster was dominated by IL-13 cells and the other was dominated by control cells). We identified further subgroups of ciliated cells that proved functionally distinct by carrying out dataset dimensionality reduction and SNN clustering on the two ciliated clusters alone. For this, we used the top three PC dimensions based on the top 1,278 most informative genes to cluster cells (resolution = 0.7), yielding four clusters, which we overlaid, along with the four secretory cell clusters, onto the tSNE plot (Figure 5B).

Plotting expression across cells

We overlaid characteristic expression of three major cell types in the airway epithelium (ciliated, secretory, and basal cells) onto tSNE plots by measuring mean expression across cell-type specific markers in each cell and then identifying cells as being characteristic of a given cell type if mean expression for that cell type was above the 70th percentile while falling below the 70th percentile for the other two cell types. For ciliated cell markers, we used 32 genes annotated to the Gene Ontology (GO) 2017 terms, "cilium movement" and "cilium-dependent cell motility." For secretory markers, we used 18 genes known to be highly expressed in airway epithelial secretory cells (*B4GALT5*, *WFDC2*, *SLPI*, *MECOM*, *ALDH1A1*, *SERPINB3*, *SERPINB4*, *ADH7*, *PIGR*, *BPIFB1*, *SCGB1A1*, *KRT4*, *SLC16A9*, *SLC6A14*, *MUC5AC*, *MUC5B*, *CD55*, *TFF3*). For the basal cell signature, we used 574 genes shown to be expressed at least 10-fold more in basal epithelial cells than in cells of the differentiated airway epithelium (Hackett et al., 2011).

For overlaying group expression in dot plots for panels of genes, we plotted normalized expression along a continuous color scale. All heatmaps show scaled normalized gene expression (or the average of expression across a function gene panel) along a continuous color scale across cells and were produced using Heatmap3 (Zhao et al., 2014). Break scales were set as indicated in the color legends.

For plots of expression across functional gene groups in heatmaps (see Figures 3B and 4A), violin plots (see Figure 4C), and boxplots (see Figures 5E, 5F, 6B, 6C, S4B, and S4C, mean expression across overlapping genes annotated for significantly enriched terms or pathways were used (see the "Functional enrichment analysis" section below for the libraries used), except in the cases outlined below.

The functional gene groups plotted in log fold change scatterplots in Figures 3C, 4B, and S4D contained the following genes: Ion transport ATPases: *ATP1A1*, *ATP1B1*, *ATP13A5*, *ATP6V0E1*, *ATP7B*, *ATP12A*; Solute carriers: *SLC5A8*, *SLC9A9*, *SLC9B2*, *SLC12A2*, *SLC22A23*, *SLC31A1*, *SLC37A1*, *SLC38A6*, *SLC39A7*, *SLC39A8*, *SLCO3A1*, *SLCO4C1*, *SLC6A14*; Endopeptidase inhibitors: *CAPN14*, *CSTB*, *FETUB*, *SERPINB2*, *SERPINB6*, *SERPINB10*, *SPINK5*, *CSTA*, *TIMP1*, *SERPINB4*, *SERPINB3*; MUC5AC/mucin-related: *FCGBP*, *GSN*, *ITLN1*, *MUC5AC*, *SCIN*; Glycosylation-related: *ADAMTSL3*, *B3GNT6*, *B3GNT2*, *CHST6*, *GALK2*, *GALNT1*, *GCNT3*, *FUT8*, *GALNT3*; Pro-inflammatory: *ALOX15*, *ANXA3*, *CCL26*, *CD36*, *DDX58*, *LGALS7*, *NOS2*, *RIPK2*, *SH2D1B*; Reductases: *AKR1C2*, *AKR1C3*, *DHRS3*, *DHRS9*, *GLUD1*, *RDH10*, *STEAP1B*, *STEAP4*; Innate immunity: *ABCA13*, *CP*, *CYP2B7P*, *GLUL*, *GSTA1*, *GSTA2*, *LYN*, *SCGB1A1*, *SCGB3A1*, *WFDC2*, *CD74*, *CXCL1*, *CXCL17*, *IL18*, *S100A2*, *S100A6*, *S100A8*, *S100A9*, *LCN2*; Cilia related (Figure 4B only): *DNAH5*, *ARMC4*, *EFHC1*, *CFAP46*, *DNAH9*, *CFAP54*, *DRC3*, *CEP126*, *PCM1*, *IFT81*, *DZIP1L*, *RFX3*, *CC2D2A*, *DYNC2H1*, *TTC21B*, *DYNLRB2*, *DNAH3*, *DNAH7*, *KIF21A*.

The "IL-13 markers" used in boxplots in Figure 5E included the following genes for ciliated cells: *PRB1*, *CST1*, *CST4*, *DPP4*, *SERPINB10*, *SERPINB13*, *GALNT7*, *FCGBP*, *SH2D1B*, *GSN*; and the following genes for secretory cells: *PRB1*, *MUC5AC*, *CST1*, *CST4*, *DPP4*, *POSTN*, *CDH26*, *SLC7A1*, *GALNT7*, *SH2D1B*. The "Innate immunity genes" used in boxplots in Figure 5E included the following genes for ciliated cells: *SCGB1A1*, *SCGB3A1*, *BPIFA1*, *S100A2*, *GSTA1*, *CYP2B7P*; and the following genes for secretory cells: *GSTA3*, *GSTA2*, *AKR1C1*, *GSTA1*, *MGST1*, *SCGB1A1*, *SCGB3A1*, *BPIFA1*, *BPIFB1*, *AKR1C1*, *AKR1C2*, *CXCL*.

Differential gene expression analysis

Differential expression (DE) for each gene between various single cell groups specified in the text was tested using a non-parametric Wilcoxon rank sum test carried out with Seurat. Except where noted, we limited each comparison to genes exhibiting both an estimated log fold change > +0.25 and detectable expression in > 10% of cells in one of the two groups being compared. We corrected for multiple hypothesis testing by calculating false discovery rate (FDR)-adjusted p values using the Benjamini-Hochberg method. Genes were considered to be differentially expressed when FDR < 0.05.

In the acute stimulation scRNA-seq analysis, when investigating which control secretory cell types (c5 or c7) were most similar to which IL-13-secretory cell types (c6 or c8), our approach was to first establish which genes were upregulated in control cells of groups c5 and c7 relative to each other as well as in IL-13 cells from groups c6 and c8 relative to each other using DE analysis. This allowed us to obtain "cell type signature" for the two pairs of secretory populations within their respective treatment milieus. We then compared overlap of these defining genes between control and IL-13 populations to identify analogous populations that share gene signatures (see Figures S2C and S2D).

When defining cell states recovered in the chronic stimulation dataset in terms of those recovered in the acute stimulation dataset, we carried out DE analysis among pairs of clusters belonging to the same cell type (ciliated and secretory) and treatment (BSA and

IL-13) and then compared differentially expressed gene (DEG) lists from these comparisons with those from parallel comparisons we'd carried out previously for the chronic stimulation dataset (see [Figures S3B](#) and [S3C](#)).

When investigating the chronic IL-13 response, we compared IL-13 cells within each of the IL-13 cell-dominated secretory clusters (mucus and defense secretory) to control cells within their respective control cell-dominated secretory cluster. We did the same for ciliated cells, but lumping together the ciliated subclusters belonging to the same treatment group. To construct the density plots in [Figure 5C](#), we obtained IL-13 DEGs for secretory cells by lumping the defense and mucus-focused subgroups together for both acute and chronic stimulation datasets. We then subtracted acute log fold changes from chronic log fold changes for each overlapping gene for secretory and ciliated cells in turn.

To obtain genes more activated with chronic stimulation compared to acute stimulation, we repeated DE analyses for both acute and chronic datasets between control and IL-13-stimulated cells, stratified by cell membership to secretory (combined) and ciliated clusters. To allow us to evaluate more subtle patterns, for these DE tests we did not exclude genes with < 0.25 log fold change. Genes were considered "significantly" more responsive with chronic than acute stimulation if either 1) chronic FDR was < 0.05 while acute FDR was < 0.05 and chronic log fold change was at least 0.1 higher than acute log fold change or 2) chronic and acute FDRs were both < 0.05 , but chronic log fold change was at least 0.25 higher than acute log fold change. It is from these lists of genes with a stronger response after chronic stimulation that enriched gene sets were obtained for [Figures 5E](#) and [5F](#).

Functional enrichment analysis

We tested for gene overrepresentation of all target lists within a panel of annotated gene databases (Gene Ontology [GO] Biological Process [BP] 2017, GO Molecular Function [MF] 2017, GO Cellular Component [CC] 2017, Kyoto Encyclopedia of Genes and Genomes [KEGG] 2016, and Reactome 2016) using hypergeometric tests implemented with Enrichr ([Chen et al., 2013](#)), as automated using the python script, EnrichrAPI (<https://github.com/russell-stewart/enrichrAPI>). We report only terms and pathways that were enriched with $FDR < 0.05$.

Lineage trajectories

We constructed lineage trajectories for both the defense and mucus-focused secretory cell populations, in turn, to better understand the transcriptional regulators that govern the transition from normal secretory cells to T2-induced cells upon stimulation with IL-13. To produce these trajectories, we used Monocle v2.8 ([Trapnell et al., 2014](#)) to first carry out dimensionality reduction using the DDRTree algorithm, and to then order cells along a trajectory of pseudotime (using Monocle's `orderCells` function) based on their expression across the 500 most differentially expressed genes (sorted by FDR) between control and IL-13-dominated clusters (inferred using Monocle's `differentialGeneTest` function). For the top informative genes from each of the two groups of cells, based on the combined mean and dispersion of expression (2,116 and 2,699 genes for defense and mucus-focused cells, respectively), we tested for differential expression as a function of pseudotime. Of the pseudotime-dependent genes ($FDR < 0.05$), there were 16 identified as transcription regulators by Ingenuity Pathway Analysis (IPA) that were significantly associated with pseudotime in both defense and mucus-secretory cell trajectories ([Figure 3D](#)). Because pseudotime scaling was the same for the two sets of cells, we overlaid relative expression, as well as smoothed expression curves, of exemplar regulators for the two trajectories across a common pseudotime ([Figure 3D](#)).

Differential protein abundance

For all proteins observed in at least two samples, we used edgeR ([Robinson et al., 2010](#)) to investigate differential abundance in response IL-13. To do this, raw spectral counts were normalized with scaling factors inferred using the weighted trimmed mean of M-values (TMM) method, and then for each protein, tagwise negative binomial dispersions were estimated using Cox-Reid profile-adjusted likelihoods, after which proteins fitted to a general linear model were tested for differential abundance between IL-13 and control samples, accounting for donor pairing, using an empirical Bayes quasi-likelihood F-test. We used Benjamini-Hochberg-derived $FDR < 0.05$ as a cutoff for inferring differentially secreted proteins.

For plotting of protein abundance in boxplots ([Figures 5B](#) and [S4B](#)) we used spectral count data normalized by size factors calculated using the median ratio method in DESeq2 ([Love et al., 2014](#)).

Analyzing ciliary beat frequency

To estimate the shift in CBF induced by chronic stimulation of IL-13 for pre- and post-washed inserts separately, we used the data from each washing regime in turn to fit linear mixed-effects models (LMM) that model the effects of IL-13 treatment (fixed effect) and donor identity (random effect) on CBF. To estimate the interaction between IL-13 treatment and washing status, we used a combined pre- and post-washed dataset to fit an LMM that models the effects of IL-13 treatment (fixed effect), wash status (fixed effect), donor identity (random effect), and an interaction between IL-13 treatment and wash status (fixed effect). Model coefficients as well as degrees of freedom and p values based on Satterthwaite approximations were calculated using the lmerTest package ([Kuznetsova et al., 2017](#)). The CBF experiment was carried out using both top-down and profile imaging. Full results from these models are in [Table S1](#).

Normalization of bulk RNA-seq data

Prior to plotting expression in boxplots, we normalized counts by size factors calculated using DESeq2. For plotting expression in the heatmap and for carrying out weighted gene co-expression network analysis (WGCNA, discussed below), we used VST counts as a way to minimize mean-dependence of variation in expression.

Assignment to type 2-high/low status

To identify T2H and T2L individuals within the *in vivo* dataset, we carried out weighted gene co-expression network analysis (WGCNA) to detect modules of co-expressed genes, which may share common biological functions (Zhang and Horvath, 2005). Briefly, the WGCNA method measures pairwise Pearson correlations among all expressed genes in the dataset, constructs a gene network based on these correlations, calculates topological overlap among genes in the network, and then, by carrying out hierarchical clustering of a distance metric based on the topological overlap matrix, identifies discrete clusters of genes. We ran the method using 17,473 genes and 695 samples. We set the soft-thresholding power to 9, which best maximized the number of connections in the gene network, while still meeting the scale-free network assumptions of the method, and we retained the direction of correlations among indirect connections in the network (i.e., analysis was 'signed'). Minimum module size was set to 30 and the deepSplit parameter was set to 2.

WGCNA identified 28 modules, one of which was highly enriched for known T2H markers, including *IL1RL1*, *CLCA1*, and *POSTN*. We hierarchically clustered GALA II samples based on expression of this module and used the first split as the basis for assignment to T2H and T2L status groups.

Cell Reports, Volume 32

Supplemental Information

Single-Cell and Population Transcriptomics

Reveal Pan-epithelial Remodeling

in Type 2-High Asthma

Nathan D. Jackson, Jamie L. Everman, Maurizio Chioccioli, Luigi Feriani, Katherine C. Goldfarbmuren, Satria P. Sajuthi, Cydney L. Rios, Roger Powell, Michael Armstrong, Joe Gomez, Cole Michel, Celeste Eng, Sam S. Oh, Jose Rodriguez-Santana, Pietro Cicuti, Nichole Reisdorph, Esteban G. Burchard, and Max A. Seibold

Figure S1




Figure S1 (related to Figure 2). Characterization of cell types in the human airway epithelium *in vitro*

(A) *Left*, Immunofluorescence (IF) labeling of ALI-differentiated human AEC cultures in profile views show prevalence of MUC5AC⁺ (red) and MUC5B⁺ (green) cells in two replicate inserts for the two HTEC donors used for scRNA-seq. Two example fields are shown for each replicate. Scale bar = 130 μm; DAPI labeling of nuclei (blue).

Right, IF quantification of MUC5AC⁺ and MUC5B⁺ cells across multiple fields for each replicate (N fields, from left to right = 6, 6, 11, 7). Bars give the mean number of cells across fields and error bars give standard error.

(B) *Left*, Immunofluorescence (IF) labeling of ALI-differentiated human AEC cultures in profile views show prevalence of SCGB1A1⁺ (green) cells in two replicate inserts for the two HTEC donors used for scRNA-seq. Two example fields are shown for each replicate. Scale bar = 130 μm; ACT labeling (red) and DAPI labeling of nuclei (blue). *Right*, IF quantification of SCGB1A1⁺ cells across multiple fields for each replicate (N fields, from left to right = 8, 5, 8, 8). Bars give mean number of cells across fields and error bars give standard error.

(C) Box plots of mean expression for ciliated cell signature genes across unsupervised clusters show that ciliated cell genes reach their highest expression in clusters c1 – c4. Expression in these four clusters is significantly higher than in each of the other clusters based on one-sided Wilcoxon signed-rank tests (p-value < 0.05).

(D) Box plots of mean expression for secretory signature genes across unsupervised clusters show that secretory genes reach their highest expression in clusters c5 – c9. Expression in these five clusters is significantly higher than in each of the other clusters based on one-sided Wilcoxon signed-rank tests (p-value < 0.05).

(E) Box plots of mean expression for basal cell signature genes across unsupervised clusters show that basal cell genes are uniquely characteristic of c9. Expression in c9 is significantly higher than in each of the other clusters based on one-sided Wilcoxon signed-rank tests (p-value < 0.05).

Figure S2




Figure S2 (related to Figure 3). Characterization of secretory cell populations in the *in vitro* airway epithelium

(A) Box plots showing that expression of genes annotated for Apoptosis or Cell cycle (KEGG pathways) was not increased by acute IL-13 stimulation in any of the secretory cell populations. P-values are based on one-sided Wilcoxon signed-rank tests.

(B) Related to Figure 3A. *Left*, Bar plots showing quantification of the average percentage of MUC5AC⁺ only, SCGB1A1⁺ only, and dual MUC5AC⁺/SCGB1A1⁺ cells relative to the total of MUC5AC and SCGB1A1-expressing cells across five top-down IF images for each of three HTEC donor cells (T73, T76, and T79) differentiated using ALI and then stimulated with IL-13 or BSA for 48 hours (acute stimulation). Average percentages across the three donors were 79.12% (SCGB1A1⁺), 15.11% (MUC5AC⁺), and 5.77% (dual⁺) in the control (BSA) condition and 19.72% (SCGB1A1⁺), 48.04% (MUC5AC⁺), and 32.24% (dual⁺) with IL-13. *Right*, similar IF quantification based on five top-down images and same magnification as in the left plots for the two tracheal donors used for scRNA-seq (T71 and T72).

(C) Description of differential expression (DE) analyses carried out to detect genes that define cell states within IL-13 and control-dominant secretory cell populations. tSNE plot and cluster assignments for secretory populations are as in Figure 2B. DE was performed between IL-13 cells in the IL-13-dominant secretory clusters, c6 and c8, and between control cells in control-dominant secretory clusters, c5 and c7. In addition, DE was performed between IL-13 cells in the basal-secretory cluster, c6, and the remaining IL-13-dominant clusters (c6 and c8 combined) as well as between control cells in c6 and the remaining control-dominant clusters (c5 and c7 combined).


(D) Venn diagrams depicting overlap of upregulated DEGs for each secretory and basal-like population, showing that c5 and c6 populations (and correspondingly, c7 and c8 populations) represent analogous cell states responding differently to control and IL-13 environments. Further supporting the c5 to c6 and c7 to c8 conversions, we observed similar frequencies of these population pairs (c5 [35%] and c6 [38%] versus c7 [23%] and c8 [22%]) within their respective control and IL-13 cultures.

(E) Immunofluorescence (IF) labeling of ALI-differentiated human AEC cultures stimulated with BSA for 48 hours (top) shows that, while difficult to detect transcriptionally, MUC5B is amply present and dominant over MUC5AC in baseline epithelia. Bar plots (bottom) showing quantification of the average percentage of MUC5AC⁺ only, MUC5B⁺ only, and dual MUC5AC⁺/MUC5B⁺ cells relative to the total of MUC5AC and MUC5B-expressing cells across IF images from two tracheal donors (T147 and T148) and 15 fields of view counted per sample.


(F) Monocle lineage trajectories for defense secretory (top) and mucus secretory cells (bottom), modeling the transition from baseline cells into those responding to an IL-13 environment. *Left*, cells colored by cluster identity; *Right*, cells colored by location along pseudotime.

Figure S3



A



B



C



D




Figure S3 (related to Figure 5). Characterizing single cell populations in the chronic stimulation dataset and comparing them with populations in the acute stimulation dataset

(A) Same tSNE plot as in Figure 5B, where cells are colored by whether they exhibit ciliated (green) or secretory (brown) cell gene signatures based on their mean expression of cell type-defining gene sets (the same sets used to define cells in the acute stimulation dataset; see Figure 2C).

(B) Same tSNE plot as in **A** showing clusters of the chronically stimulated dataset. Arrows identify populations compared in differential expression analyses to obtain cluster-specific gene signatures. These signatures were compared with signatures from analogous comparisons in the acute stimulation dataset in **C**.

(C) Heat maps that illuminate analogous clusters between chronic and acute stimulation datasets. For ciliated cells (top) and secretory cells (bottom), degree of overlap between signature genes in acute dataset clusters and chronic dataset clusters is shown, revealing that cell states analogous to mature ciliated cell clusters (c3 and c4) and secretory cell clusters (c5 – c8) in the acute stimulation dataset can also be found in the chronic stimulation dataset.

(D) Pie charts (top) and bar plot (bottom) showing differences in the proportional distribution of cell types as well as cell states within each major cell group (ciliated and secretory) between control and IL-13-stimulated epithelia in the chronic stimulation dataset.

Figure S4




Figure S4 (related to Figure 6). Effects of IL-13 on the insoluble (mucus) secretome are commensurate with those observed in the soluble secretome.

(A) Heat map of normalized spectral counts for apical secretome proteins from the insoluble (mucus) fraction that were significantly up- or downregulated with IL-13. Data based on paired HBECs from six donors.

(B) Box plots comparing mucus secretome protein abundance between control and IL-13-stimulated samples for proteins or enriched terms upregulated with IL-13. FDRs are based on DE analysis, p-values are based on one-sided Wilcoxon tests.

(C) Box plots comparing mucus secretome protein abundance between control and IL-13-stimulated samples for proteins or enriched terms downregulated with IL-13. FDRs are based on DE analysis, p-values are based on one-sided Wilcoxon tests.

(D) Scatter plot comparing the chronic transcriptomic secretory response to IL-13 with the apically secreted insoluble (mucus) protein response. Point coordinates are $y = \log$ fold changes in gene expression with IL-13 in secretory cells (clusters c5 – c9) in the chronic stimulation dataset and $x = \log$ fold changes in protein abundance with IL-13. All DEGs in the transcriptome dataset also in the secretome dataset are shown. Colored points refer to response molecules that are related to one of the specified function categories (same categories as in Figure 3C and Figure 4B).

(E) Scatter plot comparing the chronic transcriptomic secretory response to IL-13 with the apically secreted soluble protein response. Point coordinates are $y = \log$ fold changes in gene expression with IL-13 in secretory cells (clusters c5 – c9) in the chronic stimulation dataset and $x = \log$ fold changes in protein abundance with IL-13. All DEGs in the transcriptome dataset also in the secretome dataset are shown. Colored points refer to response molecules that are related to one of the specified function categories (same categories as in Figure 3C and Figure 4B).

Figure S5




Figure S5 (related to Figure 7). IL-13 responses observed using AEC cultures mirror secretory changes in the *in vivo* airway epithelium.

Bar plots showing overlap of the *in vitro* airway epithelial response, as observed in different cell types and datasets, and the response to T2 inflammation *in vivo*.

Table S1 (related to Figure 6). Summary results for fixed terms from linear mixed models that predict CBF as a function of IL-13 treatment (in pre- and post-washed datasets separately) or as a function of IL-13 treatment, wash status, and their interaction (in the combined dataset). Degrees of freedom (DF) and p-values are based on Satterthwaite approximations.

Variable	Estimate	Std. error	t value	DF (Satt)	p-value (Satt)
A. Top-down imaging					
<i>Marginal pre-washed treatment effect</i>					
Intercept	9.16	0.30	30.76	5.02	6.46E-07
Treatment (IL-13 compared to Control)	-2.15	0.03	-63.00	19671.98	<2.00E-16
<i>Marginal post-washed treatment effect</i>					
Intercept	9.50	0.52	18.33	5.02	8.62E-06
Treatment (IL-13 compared to Control)	-1.13	0.05	-21.90	17948.48	<2.00E-16
<i>Combined pre- and post-washed treatment effects</i>					
Intercept	9.18	0.37	25.14	5.04	1.71E-06
Treatment (IL-13 compared to BSA, pre-wash)	-2.19	0.04	-51.18	37624.60	<2.00E-16
Wash (post-wash compared to pre-wash, control)	0.32	0.04	8.12	37624.23	4.44E-16
Treatment:Wash (post-wash IL-13 shift compared to pre-wash IL-13 shift)	1.08	0.06	17.48	37624.26	<2.00E-16
B. Profile imaging					
<i>Marginal pre-washed treatment effect</i>					
Intercept	11.50	0.30	38.73	52.00	<2.00E-16
Treatment (IL-13 compared to Control)	-4.68	0.42	-11.15	52.00	<2.00E-16
<i>Marginal post-washed treatment effect</i>					
Intercept	10.71	0.47	22.81	1.54	6.26E-03
Treatment (IL-13 compared to Control)	0.84	0.54	1.54	33.01	1.32E-01
<i>Combined pre- and post-washed treatment effects</i>					
Intercept	11.56	0.36	31.78	3.36	2.74E-05
Treatment (IL-13 compared to BSA, pre-wash)	-4.68	0.42	-11.01	85.00	<2.00E-16
Wash (post-wash compared to pre-wash, control)	-0.87	0.45	-1.92	85.49	5.76E-02
Treatment:Wash (post-wash IL-13 shift compared to pre-wash IL-13 shift)	5.52	0.68	8.09	85.01	3.73E-12

Table S2 (related to STAR Methods). Description of tracheal sample donors.

	Donor 1 (T71)	Donor 2 (T72)
Age (years)	64	52
Sex	Female	Female
Smoking status	Former smoker (1pk/wk) x 3y	Current smoker (0.5 pk/d) x 40y
Disease status	No known diseases	Smoking-induced asthma (diagnosed 22 years prior)

Table S3 (related to STAR Methods). Description of bronchial sample donors. Note that the soluble apical samples are a subset of the insoluble apical samples. P-values are from t-tests for mean differences between subject classes.

Insoluble apical samples			
	Control Subjects	Asthmatic Subjects	p-value
Sample Size	4	10	---
Age (years)	54.0 +/- 15.81	50.2 +/- 17.47	0.7132
Sex (% female)	75%	60.00%	0.5967
Smoker	0 / 4	0 / 10	---
Soluble apical samples			
	Control Subjects	Asthmatic Subjects	p-value
Sample Size	3	3	---
Age (years)	60.33 +/-11.59	43.67 +/-26.10	0.3693
Sex (% female)	67%	33.30%	0.4142
Smoker	0 / 3	0 / 3	---

Table S4 (related to STAR Methods). Description of GALA II donors with RNA-seq data used in this study.

	Control Subjects	Asthmatic Subjects
Sample size	242	431
Sex (% female)	139 (57.4)	212 (49.0)
Age (years)	14.1 ± 3.1	14.0 ± 3.3
BMI (kg/m ²)	22.9 ± 5.3	24.3 ± 6.9
Total IgE (kU/L)	330.1 ± 566.7	521.3 ± 687.0
Eosinophils (x10 ³ /μl)	3.7 ± 2.9	4.9 ± 3.9
FeNO (ppb)	19.1 ± 16.2	30.5 ± 29.4
% FEV1	94.0 ± 13.7	88.2 ± 16.8

Table S5 (related to STAR Methods). Summary of single cell yield and mapping results, partitioned by experiment, chip, donor, and treatment.

Experiment	Chip	Donor	Treatment	N. lanes	N. cells	mean N. reads	mean N. UMIs	mean N. genes	mean % mapped	mean % mapped to genes	mean % mapped to mito genes
acute	91497	T71	BSA	3	256	392,394	7,163	2,411	79.03	69.48	7.18
acute	91497	T71	IL13	3	280	657,423	12,574	3,737	83.30	73.54	8.73
acute	91497	T72	BSA	3	250	514,443	9,982	3,100	82.60	73.34	9.11
acute	91497	T72	IL13	3	264	752,442	14,975	4,219	83.51	73.89	10.37
acute	94576	T71	BSA	3	324	420,146	8,622	2,960	84.96	74.43	6.56
acute	94576	T71	IL13	3	347	331,486	7,090	2,594	84.66	74.76	6.66
acute	94576	T72	BSA	3	330	340,246	7,309	2,636	84.78	74.93	7.57
acute	94576	T72	IL13	3	334	345,070	7,554	2,707	84.39	74.66	7.97
chronic	97570	T71	BSA	3	151	331,608	7,447	2,754	86.14	76.03	11.25
chronic	97570	T71	IL13	3	279	862,818	19,254	5,525	85.19	75.27	11.70
chronic	97570	T72	BSA	3	248	902,490	20,171	5,752	84.76	75.00	10.93
chronic	97570	T72	IL13	3	124	801,609	17,893	5,179	85.48	75.87	14.68